


AOP ID and Title:AOP 571: 5 α -reductase inhibition leading to hypospadias in male (mammalian) offspring**Short Title: 5 α -reductase inhibition leading to hypospadias****Graphical Representation****Authors**

Emilie Elmelund; National Food Institute, Technical University of Denmark, Lyngby, DK-2800, Denmark

Monica K. Draskau; National Food Institute, Technical University of Denmark, Lyngby, DK-2800, Denmark

Henrik Holbech; Department of Biology, University of Southern Denmark, DK-5230, Odense M, Denmark

Terje Svingen; National Food Institute, Technical University of Denmark, Lyngby, DK-2800, Denmark

Status**Author status****OECD status OECD project SAAOP status**

Author status**OECD status OECD project SAAOP status**

Under development: Not open for comment. Do not cite

Abstract

This AOP links *in utero* inhibition of 5 α -reductase with hypospadias in male offspring. Hypospadias is a common reproductive disorder with a prevalence of up to ~1/125 newborn boys, though with high inter-country variability (Leunbach et al., 2025; Paulozzi, 1999). Developmental exposure to endocrine disrupting chemicals is suspected to contribute to some cases of hypospadias (Mattiske & Pask, 2021). Hypospadias can be indicative of fetal disruptions to male reproductive development, and is associated with short anogenital distance and cryptorchidism (Skakkebaek et al., 2016). Thus, hypospadias is included as a genital abnormality in OECD test guidelines (TG) for developmental and reproductive toxicity (TG 414, 416, 421/422, and 443; (OECD, 2016b, 2016a, 2018a, 2018b, 2021)), as both a measurement of adverse reproductive effects and a direct clinical adverse outcome.

5 α -reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT). In normal male reproductive development, DHT activates the androgen receptor (AR) in peripheral reproductive tissues to drive differentiation of the male phenotype, including development of the penis. While testosterone also acts directly at the AR, DHT is 5-10 times more potent, and in peripheral tissues, conversion to DHT is necessary for proper masculinization (Amato et al., 2022; Davey & Grossmann, 2016). This AOP delineates the evidence that inhibition of 5 α -reductase reduces DHT levels and consequently AR activation, thereby disrupting penis development and causing hypospadias. The AOP is supported by *in vitro* experiments upstream of AR activation and by *in vivo* and human case studies downstream of AR activation. Downstream of a reduction in AR activation, the molecular mechanisms of hypospadias development are not fully delineated, highlighting a knowledge gap in this AOP. Thus, the AOP has potential for inclusion of additional KEs and elaboration of molecular causality links, once these are established. Given that hypospadias is both a clinical and toxicological endpoint, this AOP is considered highly relevant in a regulatory context.

AOP Development Strategy**Context**

This AOP is a part of an AOP network for reduced androgen receptor activation causing hypospadias in male offspring. The other AOPs in this network are AOP-477 ('Androgen receptor antagonism leading to hypospadias in male (mammalian) offspring'), and AOP-570 ('Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring'). The purpose of the AOP network is to organize the well-established evidence for anti-androgenic mechanisms-of-action leading to hypospadias, thus informing predictive toxicology and identifying knowledge gaps for investigation and method development.

This work received funding from the European Food and Safety Authority (EFSA) under Grant agreement no. GP/EFSA/PREV/2022/01 and from the Danish Environmental Protection Agency under the Danish Center for Endocrine Disruptors (CeHoS).

Strategy

The OECD AOP Developer's Handbook was followed alongside pragmatic approaches (Svingen et al., 2021).

KEs and upstream KER1880 ('inhibition, 5 α -reductase leads to decrease, DHT levels'), KER-1935 ('decrease, DHT levels leads to decrease, AR activation'), and KER-2124 ('decrease, AR activation leads to altered, transcription of genes by AR') were considered canonical knowledge and part of an upstream anti-androgenic network developed using mainly key review articles (Draskau et al., 2024). The non-adjacent KER-2828 linking reduced AR activation with hypospadias was developed using a systematic weight-of-evidence approach, following methodology outlined in (Holmer et al., 2024). Articles were retrieved by literature searches in PubMed and Web of Science and extensive screening using pre-defined inclusion and exclusion criteria. Evaluation of methodological reliability of *in vivo* animal studies was performed using the Science in Risk Assessment and Policy (SciRAP) online tool. As there are currently no *in vivo* methods to measure AR activation in mammals, six chemicals with known anti-androgenic mechanisms-of-action were chosen for the empirical evidence for this KER. To supplement the *in vivo* toxicity studies, human case studies and epidemiologic studies were included in the KER. These studies were not systematically evaluated for reliability but served as supporting evidence.

Regarding the inclusion of KEs and KERs, the rationale for the upstream anti-androgenic network is detailed in (Draskau et al., 2024). The link between the upstream network, more specifically KE-286 ('altered, transcription of genes by AR'), and AO-2082 ('hypospadias') likely contains a tissue-specific KE that has not been developed, as sufficient evidence is not yet available. Thus currently, the strongest evidence linking the upstream anti-androgenic network to hypospadias is captured by KER-2828.

Summary of the AOP**Events****Molecular Initiating Events (MIE), Key Events (KE), Adverse Outcomes (AO)**

Sequence	Type	Event ID	Title	Short name
	MIE	1617	Inhibition, 5α-reductase	Inhibition, 5 α -reductase
	KE	1613	Decrease, dihydrotestosterone (DHT) levels	Decrease, DHT level
	KE	1614	Decrease, androgen receptor activation	Decrease, AR activation
	KE	286	Altered, Transcription of genes by the androgen receptor	Altered, Transcription of genes by the AR
	AO	2082	Hypospadias, increased	Hypospadias

Key Event Relationships

Upstream Event	Relationship Type	Downstream Event	Evidence	Quantitative Understanding
Inhibition, 5α-reductase	adjacent	Decrease, dihydrotestosterone (DHT) levels	High	
Decrease, dihydrotestosterone (DHT) levels	adjacent	Decrease, androgen receptor activation	High	
Decrease, androgen receptor activation	adjacent	Altered, Transcription of genes by the androgen receptor	High	
Decrease, androgen receptor activation	non-adjacent	Hypospadias, increased	High	

Stressors

Name Evidence

Finasteride

Overall Assessment of the AOP

Domain of Applicability

Life Stage Applicability

Life Stage Evidence

Foetal High

Taxonomic Applicability

Term Scientific Term Evidence Links

human Homo sapiens High [NCBI](#)

rat Rattus norvegicus High [NCBI](#)

mouse Mus musculus Moderate [NCBI](#)

Sex Applicability

Sex Evidence

Male High

Although the upstream part of the AOPN has a broad applicability domain, the overall AOPN is considered only applicable to male mammals during fetal life, restricted by the applicability of KER-2828 ('Decrease, AR activation leads to hypospadias'). The term hypospadias is mainly used for describing malformation of the male, and not female, external genitalia. Some studies refer to hypospadias in females, but these have not been reported to be caused by exposure to 5 α -reductase inhibitors, and the mechanisms behind these malformations are likely different from the mechanisms in males (Greene, 1937; Stewart et al., 2018). The genital tubercle is programmed by androgens to differentiate into a penis in fetal life in the masculinization programming window, followed by the morphologic differentiation (Welsh et al., 2008). In humans, hypospadias is diagnosed at birth and can also often be observed in rats and mice at this time point, although the rodent penis does not finish developing until a few weeks after birth (Baskin & Ebbers, 2006; Sinclair et al., 2017). The disruption to androgen programming leading to hypospadias thus take place during fetal life, but the AO is best detected postnatally. Specifically, the masculinization

programming window (~gestational days (GD) 16-20 in rat, presumably gestational weeks (GW)8-14 in humans) is the primary fetal window of applicability, but effects outside of this window in fetal life, after androgen production has started, cannot be excluded. Regarding taxonomic applicability, hypospadias has mainly been identified in rodents and humans, and the evidence in this AOP is almost exclusively from these species. It is, however, biologically plausible that the AOP is applicable to other mammals as well, given the conserved role of androgens in mammalian reproductive development, and hypospadias has been observed in many domestic animal and wildlife species, albeit not coupled to 5 α -reductase inhibition.

Essentiality of the Key Events

Event	Evidence	Uncertainties and inconsistencies
MIE-1617 Inhibition, 5 α -reductase (high)	Biological plausibility provides strong support for the essentiality of this event, as DHT (produced by 5α-reductase) is one of the primary drivers of penis development. <i>In utero</i> exposure to the 5α-reductase inhibitor finasteride can cause hypospadias in male rats (Clark et al., 1993) Human case studies of 5α-reductase deficiency support the essentiality of this KE, as mutations in 5α-reductase can cause low DHT levels and associated hypospadias in males (Robitaille & Langlois, 2020). See also Table 4 in KER-2828 listing disruptions of AR activity associated with hypospadias in humans.	In the human case studies, DHT is only measured postnatally and not in fetal life.

KE-1613 Decrease, DHT levels (moderate)	Biological plausibility provides strong support for the essentiality of this event, as DHT is a ligand of the AR and one of the primary drivers of penis development. Indirect evidence of impact of decreased DHT levels (KE-1613) on AR activation <i>in vivo</i> (KE-1614) comes from the fact that androgen deprivation is used as treatment for prostate cancer, including 5α-reductase inhibitors, to reduce DHT levels and cancer growth (Aggarwal et al., 2010) Moreover, indirect evidence of impact of decreased DHT levels (KE-1613) on AR activation <i>in vitro</i> comes from increasing concentrations of DHT leading to increasing AR activation <i>in vitro</i> in AR reporter gene assays (OECD, 2023; Williams et al., 2017) In patients with 5α-reductase deficiency, DHT levels are reduced and hypospadias is frequently observed, as listed in Table 4 in KER-2828.	In the human case studies, DHT is only measured postnatally and not in fetal life. As hypospadias is a congenital malformation, it cannot be “reversed” by postnatal DHT treatment.
KE-1614 Decrease, AR activation (moderate)	Biological plausibility provides strong support for the essentiality of this event, as AR activation is critical for normal penis development. Conditional or full knockout of <i>Ar</i> in mice results in partly or full sex-reversal of males, including a female-like urethral opening (Willingham et al., 2006; Yucel et al., 2004; Zheng et al., 2015). Human subjects with <i>AR</i> mutations may also have associated hypospadias (as listed in Table 4 in KER-2828).	

KE-286 Altered, transcription of genes by AR (moderate)		Biological plausibility provides support for the essentiality of this event. AR is a nuclear receptor and transcription factor regulating transcription of genes, and androgens, acting through AR, are essential for normal male penis development. Genomic AR signaling is necessary and possibly sufficient to drive penis differentiation (Cunha et al., 2021) Known AR-responsive genes active in normal penis development have been thoroughly reviewed (Amato et al., 2022).	There are currently no AR-responsive genes proved to be causally involved in hypospadias, and it is known that the AR can also signal through non-genomic actions, though these alone are not sufficient for penis differentiation –and genomic AR signaling is necessary for penis development (Cunha et al., 2021; Leung & Sadar, 2017).	
Event	Direct evidence	Indirect evidence	Contradictory evidence	Overall essentiality assessment
MIE 1617	***			High
KE 1613	*	**		Moderate
KE 1614	**			Moderate
KE 286	**	*		Moderate

Weight of Evidence Summary

The confidence in each of the KERs comprising the AOP are judged as high, with both high biological plausibility and high confidence in the empirical evidence. The mechanistic link between KE-286 ('altered, transcription of genes by AR') and AO-2082 ('hypospadias') is not established, but given the high confidence in the KERs including the non-adjacent KER-2828 linking to the AO, the overall confidence in the AOP is judged as **high**.

KER	Biological Plausibility	Empirical Evidence	Rationale
KER-1880 Inhibition, 5α-reductase leads to decrease, DHT levels	High	High (canonical)	It is well established that 5α-reductase converts testosterone to DHT. <i>In vitro</i> , <i>in vivo</i> and human studies with 5α-reductase inhibitors have shown dose-dependent decreases in formation of DHT (Draskau et al., 2024).
KER-1935 Decrease, DHT levels leads to decrease, AR activation	High	High (canonical)	It is well established that DHT activates the AR. Direct evidence for this KER is not possible since KE-1614 can currently not be measured and is considered an <i>in vivo</i> effect. Indirect evidence using proxy read-outs of AR activation, either <i>in vitro</i> or <i>in vivo</i> strongly supports the relationship (Draskau et al., 2024).
KER-2124 Decrease, AR activation leads to altered, transcription of genes by AR	High	High (canonical)	It is well established that the AR regulates gene transcription. <i>In vivo</i> animal studies and human genomic profiling show tissue-specific changes to gene expression upon disruption of AR (Draskau et al., 2024).

KER-2828 Decrease, AR activation leads to hypospadias	High	High	It is well established that AR drives penis differentiation. Numerous <i>in vivo</i> toxicity studies and human case studies indirectly show that decreased AR activation leads to hypospadias, with few inconsistencies. The empirical evidence moderately supports temporal concordance for the KER. It should be recognized that the upstream KE-1614 cannot currently be measured directly (<i>in vivo</i>). Instead, empirical evidence was therefore collected for substances known to affect upstream events. This limitation is not considered to lower the strength of the evidence in this case.
---	------	------	--

Quantitative Consideration

The quantitative understanding of this AOP is judged as low.

References

- Aggarwal, S., Thareja, S., Verma, A., Bhardwaj, T. R., & Kumar, M. (2010). An overview on 5 α -reductase inhibitors. *Steroids*, 75(2), 109–153. <https://doi.org/10.1016/j.steroids.2009.10.005>
- Amato, C. M., Yao, H. H.-C., & Zhao, F. (2022). One Tool for Many Jobs: Divergent and Conserved Actions of Androgen Signaling in Male Internal Reproductive Tract and External Genitalia. *Frontiers in Endocrinology*, 13, 910964. <https://doi.org/10.3389/fendo.2022.910964>
- Baskin, L., & Ebbers, M. (2006). Hypospadias: Anatomy, etiology, and technique. *Journal of Pediatric Surgery*, 41(3), 463–472. <https://doi.org/10.1016/j.jpedsurg.2005.11.059>
- Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010). Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 95(6), 2536–2559. <https://doi.org/10.1210/jc.2009-2354>
- Chamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994). The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Research*, 22(15), 3181–3186. <https://doi.org/10.1093/nar/22.15.3181>
- Clark, R. L., Anderson, C. A., Prahallada, S., Robertson, R. T., Lochry, E. A., Leonard, Y. M., Stevens, J. L., & Hoberman, A. M. (1993). Critical Developmental Periods for Effects on Male Rat Genitalia Induced by Finasteride, a 5 α -Reductase Inhibitor. *Toxicology and Applied Pharmacology*, 119(1), 34–40. <https://doi.org/10.1006/taap.1993.1041>
- Cunha, G. R., Cao, M., Derpinghaus, A., Baskin, L. S., Cooke, P., & Walker, W. (2021). Cornification and classical versus nonclassical androgen receptor signaling in mouse penile/preputial development. *Differentiation*, 121, 1–12. <https://doi.org/10.1016/j.diff.2021.08.002>
- Davey, R. A., & Grossmann, M. (2016). Androgen Receptor Structure, Function and Biology: From Bench to Bedside. *The Clinical Biochemist. Reviews*, 37(1), 3–15.
- Draskau, M., Rosenmai, A., Bouftas, N., Johansson, H., Panagiotou, E., Holmer, M., Elmelund, E., Zilliacus, J., Beronius, A., Damdimopoulou, P., van Duursen, M., & Svingen, T. (2024). Aop Report: An Upstream Network for Reduced Androgen Signalling Leading to Altered Gene Expression of Ar Responsive Genes in Target Tissues. *Environ Toxicol Chem*, (In Press).
- Greene, R. R. (1937). Production of Experimental Hypospadias in the Female Rat. *Proceedings of the Society for Experimental Biology and Medicine*, 36(4), 503–506. <https://doi.org/10.3181/00379727-36-9287P>
- Holmer, M. L., Zilliacus, J., Draskau, M. K., Hliseníková, H., Beronius, A., & Svingen, T. (2024). Methodology for developing data-rich Key Event Relationships for Adverse Outcome Pathways exemplified by linking decreased androgen receptor activity with decreased anogenital distance. *Reproductive Toxicology*, 128, 108662. <https://doi.org/10.1016/j.reprotox.2024.108662>
- Leunbach, T. L., Berglund, A., Ernst, A., Hvistendahl, G. M., Rawashdeh, Y. F., & Gravholt, C. H. (2025). Prevalence, Incidence, and Age at Diagnosis of Boys With Hypospadias: A Nationwide Population-Based Epidemiological Study. *Journal of Urology*, 213(3), 350–360. <https://doi.org/10.1097/JU.0000000000004319>
- Leung, J. K., & Sadar, M. D. (2017). Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. *Frontiers in Endocrinology*, 8. <https://doi.org/10.3389/fendo.2017.00002>

- Mattiske, D. M., & Pask, A. J. (2021). Endocrine disrupting chemicals in the pathogenesis of hypospadias; developmental and toxicological perspectives. *Current Research in Toxicology*, 2, 179–191. <https://doi.org/10.1016/j.crtox.2021.03.004>
- OECD. (2001). *Test No. 416: Two-Generation Reproduction Toxicity* [OECD Guidelines for the Testing of Chemicals, Section 4]. OECD Publishing. <https://doi.org/10.1787/9789264070868-en>
- OECD. (2016a). *Test No. 421: Reproduction/Developmental Toxicity Screening Test*. OECD. <https://doi.org/10.1787/9789264264380-en>
- OECD. (2016b). *Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test*. OECD. <https://doi.org/10.1787/9789264264403-en>
- OECD. (2018a). *Test No. 414: Prenatal Developmental Toxicity Study*. OECD. <https://doi.org/10.1787/9789264070820-en>
- OECD. (2018b). *Test No. 443: Extended One-Generation Reproductive Toxicity Study*. OECD. <https://doi.org/10.1787/9789264185371-en>
- OECD. (2023). *Test No. 458: Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist Activity of Chemicals*. OECD. <https://doi.org/10.1787/9789264264366-en>
- Paulozzi, L. J. (1999). *International trends in rates of hypospadias and cryptorchidism*.
- Robitaille, J., & Langlois, V. S. (2020). Consequences of steroid-5 α -reductase deficiency and inhibition in vertebrates. *General and Comparative Endocrinology*, 290, 113400. <https://doi.org/10.1016/j.ygcen.2020.113400>
- Sinclair, A., Cao, M., Pask, A., Baskin, L., & Cunha, G. (2017). Flutamide-induced hypospadias in rats: A critical assessment. *Differentiation; Research in Biological Diversity*, 94, 37–57. (rayyan-427634666). <https://doi.org/10.1016/j.diff.2016.12.001>
- Skakkebaek, N. E., Rajpert-De Meyts, E., Louis, G. M. B., Toppari, J., Andersson, A.-M., Eisenberg, M. L., Jensen, T. K., Jorgensen, N., Swan, S. H., Sapra, K. J., Ziebe, S., Priskorn, L., & Juul, A. (2016). Male Reproductive Disorders And Fertility Trends: Influences Of Environment And Genetic susceptibility. *PHYSIOLOGICAL REVIEWS*, 96(1), 55–97. (WOS:000370383200003). <https://doi.org/10.1152/physrev.00017.2015>
- Stewart, M. K., Mattiske, D. M., & Pask, A. J. (2018). In utero exposure to both high- and low-dose diethylstilbestrol disrupts mouse genital tubercle development†. *Biology of Reproduction*, 99(6), 1184–1193. <https://doi.org/10.1093/biolre/i0y142>
- Svingen, T., Villeneuve, D. L., Knapen, D., Panagiotou, E. M., Draskau, M. K., Damdimopoulou, P., & O'Brien, J. M. (2021). A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation. *Toxicological Sciences*, 184(2), 183–190. <https://doi.org/10.1093/toxsci/kfab113>
- Tut, T. G., Ghadessy, F. J., Trifiro, M. A., Pinsky, L., & Yong, E. L. (1997). Long Polyglutamine Tracts in the Androgen Receptor Are Associated with Reduced *Trans* -Activation, Impaired Sperm Production, and Male Infertility¹. *The Journal of Clinical Endocrinology & Metabolism*, 82(11), 3777–3782. <https://doi.org/10.1210/jcem.82.11.4385>
- Welsh, M., Saunders, P. T. K., Fiskens, M., Scott, H. M., Hutchison, G. R., Smith, L. B., & Sharpe, R. M. (2008). Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. *Journal of Clinical Investigation*, 118(4), 1479–1490. <https://doi.org/10.1172/JCI34241>
- Williams, A. J., Grulke, C. M., Edwards, J., McEachran, A. D., Mansouri, K., Baker, N. C., Patlewicz, G., Shah, I., Wambaugh, J. F., Judson, R. S., & Richard, A. M. (2017). The CompTox Chemistry Dashboard: A community data resource for environmental chemistry. *Journal of Cheminformatics*, 9(1), 61. <https://doi.org/10.1186/s13321-017-0247-6>
- Willingham, E., Agras, K., Souza, A. J. de, Konijeti, R., Yucel, S., Rickie, W., Cunha, G., & Baskin, L. (2006). Steroid receptors and mammalian penile development: An unexpected role for progesterone receptor? *The Journal of Urology*, 176(2), 728–733. (rayyan-427634662). <https://doi.org/10.1016/j.juro.2006.03.078>
- Yucel, S., Liu, W., Cordero, D., Donjacour, A., Cunha, G., & Baskin, L. (2004). Anatomical studies of the fibroblast growth factor-10 mutant, Sonic Hedge Hog mutant and androgen receptor mutant mouse genital tubercle. *Advances in Experimental Medicine and Biology*, 545, 123–148. (rayyan-427634903). https://doi.org/10.1007/978-1-4419-8995-6_8
- Zheng, Z., Armfield, B., & Cohn, M. (2015). Timing of androgen receptor disruption and estrogen exposure underlies a spectrum of congenital penile anomalies. *Proceedings of the National Academy of Sciences of the United States of America*, 112(52), E7194–203. (rayyan-427635801). <https://doi.org/10.1073/pnas.1515981112>

Appendix 1

List of MIEs in this AOP

Event: 1617: Inhibition, 5 α -reductase

Short Name: Inhibition, 5 α -reductase

AOPs Including This Key Event

AOP ID and Name	Event Type
Aop:289 - Inhibition of 5α-reductase leading to impaired fecundity in female fish	MolecularInitiatingEvent
Aop:305 - 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	MolecularInitiatingEvent
Aop:120 - Inhibition of 5α-reductase leading to Leydig cell tumors (in rat)	MolecularInitiatingEvent
Aop:571 - 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	MolecularInitiatingEvent
Aop:576 - 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	MolecularInitiatingEvent

Biological Context

Level of Biological Organization

Molecular

Cell term

Cell term

eukaryotic cell

Domain of Applicability

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
During development and at adulthood	High

Sex Applicability

Sex	Evidence
Mixed	High

This KE is applicable to both sexes, across developmental stages into adulthood, in many different tissues, and across mammalian taxa. It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Essentially the reaction performed by the isozymes is the same, but the enzyme is differentially expressed in the body. 5 α -reductase type 1 is mainly linked to the production of neurosteroids, 5 α -reductase type 2 is mainly involved in production of 5 α -DHT, whereas 5 α -reductase type 3 is involved in N-glycosylation (Robitaille & Langlois, 2020).

The expression profile of the three 5 α -reductase isoforms depends on the developmental stage, the tissue of interest, and the disease state of the tissue. The enzymes have been identified in, for instance, non-genital and genital skin, scalp, prostate, liver, seminal vesicle, epididymis, testis, ovary, kidney, exocrine pancreas, and brain (Azzouni, 2012, Uhlen 2015).

5 α -reductase is well-conserved, all primary species in Eukaryota contain all three isoforms (from plant, amoeba, yeast to vertebrates) (Azzouni, 2012) and the enzymes are expressed in both males and females (Langlois, 2010, Uhlen 2015).

Key Event Description

This KE describes the inhibition of 5 α -reductases (3-oxo-5 α -steroid 4-dehydrogenases). These enzymes are widely expressed in tissues of both sexes and responsible for conversion of steroid hormones.

There are three isozymes: 5 α -reductase type 1, 2, and 3. The substrates for 5 α -reductases are 3-oxo (3-keto), $\Delta^{4,5}$ C19/C21 steroids such as testosterone, progesterone, androstenedione, epi-testosterone, cortisol, aldosterone, and deoxycorticosterone. The enzymatic reaction leads to an irreversible breakage of the double bond between carbon 4 and 5 and subsequent insertion of a hydride anion at carbon 5 and insertion of a proton at carbon 4. The reaction is aided by the cofactor NADPH. The substrate affinity and reaction velocity differ depending on the combination of substrate and enzyme isoform, for instance 5 α -reductase type 2 has a higher substrate affinity for testosterone than the type 1 isoform of the enzyme, and the enzymatic reaction occurs at a higher velocity under optimal conditions. Likewise, inhibitors of 5 α -reductase may exhibit differential effects depending on isoforms (Azzouni et al., 2012).

How it is Measured or Detected

There is currently (as of 2023) no OECD test guideline for the measurement of 5 α -reductase inhibition.

Assessing the ability of chemicals to inhibit the activity of 5 α -reductase is challenging, but has been assessed using transfected cell lines. This has been demonstrated in HEK-293 cells stably transfected with human 5 α -reductase type 1, 2, and 3 (Yamana et al., 2010), in CHO cells stably transfected with human 5 α -reductase type 1 and 2 (Thigpens et al., 1993), and COS cells transfected with human and rat 5 α -reductase with unspecified isoforms (Andersson & Russell, 1990). The transfected cells are typically used as intact cells or cell homogenates. Further, 5 α -reductase 1 and 2 have been successfully expressed and isolated from *Escherichia coli* with subsequent functionality allowing for examination of enzyme inhibition (Peng et al., 2020). The availability of the stably transfected cell lines and the isolated enzymes to the scientific community is unknown.

The output of the above methods could be decreased dihydrotestosterone (DHT) with increasing test chemical concentrations. Other substrates exist for the different isoforms that could be used to assess the enzymatic inhibition (Peng et al., 2020). The use of radiolabeled steroids has historic and continued use for 5 α -reductase inhibition examination (Andersson & Russell, 1990; Peng et al., 2020; Thigpens et al., 1993; Yamana et al., 2010); however, alternative methods are available, such as conventional ELISA kits or advanced analytical methods such as liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).

References

- Andersson, S., & Russell, D. W. (1990). Structural and biochemical properties of cloned and expressed human and rat steroid 5 α -reductases. *Proc. Natl. Acad. Sci. USA*, 87, 3640–3644. <https://www.pnas.org>
- Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012). The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. In *Advances in Urology*. <https://doi.org/10.1155/2012/530121>
- Langlois VS, Zhang D, Cooke GM, Trudeau VL. (2010). Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase. *Gen Comp Endocrinol*. 166(3):489-97. doi: 10.1016/j.ygcen.2009.08.004.
- Peng, H. M., Valentin-Goyco, J., Im, S. C., Han, B., Liu, J., Qiao, J., & Auchus, R. J. (2020). Expression in escherichia coli, purification, and functional reconstitution of human steroid 5 α -reductases. *Endocrinology (United States)*, 161(8), 1–11. <https://doi.org/10.1210/ENDOCR/BQAA117>
- Robitaille, J., & Langlois, V. S. (2020). Consequences of steroid-5 α -reductase deficiency and inhibition in vertebrates. In *General and Comparative Endocrinology* (Vol. 290). Academic Press Inc. <https://doi.org/10.1016/j.ygcen.2020.113400>
- Thigpens, A. E., Cala, K. M., & Russell, D. W. (1993). Characterization of Chinese Hamster Ovary Cell Lines Expressing Human Steroid 5 α -Reductase Isozymes. *The Journal of Biological Chemistry*, 268(23), 17404–17412.
- Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., Olsson, I. M., Edlund, K., Lundberg, E., Navani, S., Szigartyo, C. A. K., Odeberg, J., Djureinovic, D., Takanen, J. O., Hober, S., ... Pontén, F. (2015). Tissue-based map of the human proteome. *Science*, 347(6220). <https://doi.org/10.1126/science.1260419>
- Yamana, K., Fernand, L., Luu-The, V., & Luu-The, V. (2010). Human type 3 5 α -reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. *Hormone Molecular Biology and Clinical Investigation*, 2(3), 293–299. <https://doi.org/10.1515/HMBCI.2010.035>

List of Key Events in the AOP

Event: 1613: Decrease, dihydrotestosterone (DHT) levels

Short Name: Decrease, DHT level

Event Component

Process	Object	Action
hormone biosynthetic process	17beta-Hydroxy-2-oxa-5alpha-androstan-3-one	decreased

AOPs Including This Key Event

AOP ID and Name	Event Type
Aop:288 - Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)	KeyEvent
Aop:289 - Inhibition of 5α-reductase leading to impaired fecundity in female fish	KeyEvent
Aop:305 - 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:527 - Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) leads to Hypospadias, increased	KeyEvent
Aop:571 - 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	KeyEvent
Aop:576 - 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	KeyEvent

Biological Context

Level of Biological Organization

Tissue

Domain of Applicability

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
All life stages	Moderate

Sex Applicability

Sex	Evidence
Mixed	High

This KE is applicable to both sexes, across developmental stages and adulthood, in many different tissues and across mammals.

In both humans and rodents, DHT is important for the *in utero* differentiation and growth of the prostate and male external genitalia (Azzouni et al., 2012; Gerald & Raj, 2022). Besides its critical role in development, DHT also induces growth of facial and body hair during puberty in humans (Azzouni et al., 2012).

In mammals, the role of DHT in females is less established (Swerdlhoff et al., 2017), however studies suggest that androgens are important in e.g. bone metabolism and growth, as well as female reproduction from follicle development to parturition (Hammes & Levin, 2019).

It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Description

Dihydrotestosterone (DHT) is an endogenous steroid hormone and a potent androgen. The level of DHT in tissue or blood is dependent on several factors, such as the synthesis, uptake/release, metabolism, and elimination from the system, which again can be dependent on biological compartment and developmental stage.

DHT is primarily synthesized from testosterone (T) via the irreversible enzymatic reaction facilitated by 5α-Reductases (5α-REDs) (Swerdlhoff et al., 2017). Different isoforms of this enzyme are differentially expressed in specific tissues (e.g. prostate, skin, liver, and hair follicles) at different developmental stages, and depending on disease status (Azzouni et al., 2012; Uhlén et

al., 2015), which ultimately affects the local production of DHT.

An alternative (“backdoor”) pathway, exists for DHT formation that is independent of T and androstenedione as precursors. While first discovered in marsupials, the physiological importance of this pathway has now also been established in other mammals including humans (Renfree and Shaw, 2023). This pathway relies on the conversion of progesterone (P) or 17-OH-P to androsterone and then androstanediol through several enzymatic reactions and finally, the conversion of androstanediol into DHT probably by HSD17B6 (Miller & Auchus, 2019; Naamneh Elzenaty et al., 2022). The “backdoor” synthesis pathway is a result of an interplay between placenta, adrenal gland, and liver during fetal life (Miller & Auchus, 2019).

The conversion of T to DHT by 5 α -RED in peripheral tissue is mainly responsible for the circulating levels of DHT, though some tissues express enzymes needed for further metabolism of DHT consequently leading to little release and contribution to circulating levels (Swerdlhoff et al.).

The initial conversion of DHT into inactive steroids is primarily through 3 α -hydroxysteroid dehydrogenase (3 α -HSD) and 3 β -HSD in liver, intestine, skin, and androgen-sensitive tissues. The subsequent conjugation is mainly mediated by uridine 5'-diphospho (UDP)-glucuronyltransferase 2 (UGT2) leading to biliary and urinary elimination from the system. Conjugation also occurs locally to control levels of highly potent androgens (Swerdlhoff et al., 2017).

Disruption of any of the aforementioned processes may lead to decreased DHT levels, either systemically or at tissue level.

How it is Measured or Detected

Several methods exist for DHT identification and quantification, such as conventional immunoassay methods (ELISA or RIA) and advanced analytical methods such as liquid chromatography tandem mass spectrometry (LC-MS/MS). The methods can have differences in detection and quantification limits, which should be considered depending on the DHT levels in the sample of interest. Further, the origin of the sample (e.g. cell culture, tissue, or blood) will have implications for the sample preparation.

Conventional immunoassays have limitations in that they can overestimate the levels of DHT compared to levels determined by gas chromatography mass spectrometry and liquid chromatography tandem mass spectrometry (Hsing et al., 2007; Shiraishi et al., 2008). This overestimation may be explained by lack of specificity of the DHT antibody used in the RIA and cross-reactivity with T in samples (Swerdlhoff et al., 2017).

Test guideline no. 456 (OECD 2023) uses a cell line, NCI-H295, capable of producing DHT at low levels. The test guideline is not validated for this hormone. Measurement of DHT levels in these cells require low detection and quantification limits. Any effect on DHT can be a result of many upstream molecular events that are specific for the NCI-H295 cells, and which may differ in other models for steroidogenesis.

References

- Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012). The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. In *Advances in Urology*. <https://doi.org/10.1155/2012/530121>
- Gerald, T., & Raj, G. (2022). Testosterone and the Androgen Receptor. In *Urologic Clinics of North America* (Vol. 49, Issue 4, pp. 603-614). W.B. Saunders. <https://doi.org/10.1016/j.ucl.2022.07.004>
- Hammes, S. R., & Levin, E. R. (2019). Impact of estrogens in males and androgens in females. In *Journal of Clinical Investigation* (Vol. 129, Issue 5, pp. 1818-1826). American Society for Clinical Investigation. <https://doi.org/10.1172/JCI125755>
- Hsing, A. W., Stanczyk, F. Z., Bélanger, A., Schroeder, P., Chang, L., Falk, R. T., & Fears, T. R. (2007). Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. *Cancer Epidemiology Biomarkers and Prevention*, 16(5), 1004-1008. <https://doi.org/10.1158/1055-9965.EPI-06-0792>
- Miller, W. L., & Auchus, R. J. (2019). The “backdoor pathway” of androgen synthesis in human male sexual development. *PLoS Biology*, 17(4). <https://doi.org/10.1371/journal.pbio.3000198>
- Naamneh Elzenaty, R., du Toit, T., & Flück, C. E. (2022). Basics of androgen synthesis and action. In *Best Practice and Research: Clinical Endocrinology and Metabolism* (Vol. 36, Issue 4). Bailliere Tindall Ltd. <https://doi.org/10.1016/j.beem.2022.101665>
- OECD (2023), Test No. 456: H295R Steroidogenesis Assay, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264122642-en>.
- Renfree, M. B., and Shaw, G. (2023). The alternate pathway of androgen metabolism and window of sensitivity. *J. Endocrinol.*, JOE-22-0296. doi:10.1530/JOE-22-0296.
- Shiraishi, S., Lee, P. W. N., Leung, A., Goh, V. H. H., Swerdlhoff, R. S., & Wang, C. (2008). Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. *Clinical Chemistry*, 54(11), 1855-1863. <https://doi.org/10.1373/clinchem.2008.103846>
- Swerdlhoff, R. S., Dudley, R. E., Page, S. T., Wang, C., & Salameh, W. A. (2017). Dihydrotestosterone: Biochemistry, physiology, and clinical implications of elevated blood levels. In *Endocrine Reviews* (Vol. 38, Issue 3, pp. 220-254). Endocrine Society. <https://doi.org/10.1210/er.2016-1067>

Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., Olsson, I. M., Edlund, K., Lundberg, E., Navani, S., Szigartyo, C. A. K., Odeberg, J., Djureinovic, D., Takanen, J. O., Hober, S., ... Pontén, F. (2015). Tissue-based map of the human proteome. *Science*, 347(6220). <https://doi.org/10.1126/science.1260419>

Event: 1614: Decrease, androgen receptor activation

Short Name: Decrease, AR activation

Event Component

Process	Object	Action
androgen receptor activity	androgen receptor	decreased

AOPs Including This Key Event

AOP ID and Name	Event Type
Aop:288 - Inhibition of 17α-hydrolase/C 10.20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)	KeyEvent
Aop:305 - 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:306 - Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:307 - Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:344 - Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring	KeyEvent
Aop:372 - Androgen receptor antagonism leading to testicular cancer	KeyEvent
Aop:477 - Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring	KeyEvent
Aop:345 - Androgen receptor (AR) antagonism leading to decreased fertility in females	KeyEvent
Aop:111 - Decrease in androgen receptor activity leading to Leydig cell tumors (in rat)	MolecularInitiatingEvent
Aop:570 - Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring	KeyEvent
Aop:571 - 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	KeyEvent
Aop:575 - Decreased testosterone synthesis leading to increased nipple retention (NR) in male (rodent) offspring	KeyEvent
Aop:576 - 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	KeyEvent

Biological Context

Level of Biological Organization

Tissue

Domain of Applicability

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
------------	----------

Life Stage	Evidence
During development and at adulthood	High
Sex Applicability	
Sex	Evidence
Mixed	High
This KE is considered broadly applicable across mammalian taxa as all mammals express the AR in numerous cells and tissues where it regulates gene transcription required for developmental processes and functions. It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.	
Key Event Description	
This KE refers to decreased activation of the androgen receptor (AR) as occurring in complex biological systems such as tissues and organs <i>in vivo</i>. It is thus considered distinct from KEs describing either blocking of AR or decreased androgen synthesis. The AR is a nuclear transcription factor with canonical AR activation regulated by the binding of the androgens such as testosterone or dihydrotestosterone (DHT). Thus, AR activation can be decreased by reduced levels of steroidal ligands (testosterone, DHT) or the presence of compounds interfering with ligand binding to the receptor (Davey & Grossmann, 2016; Gao et al., 2005). In the inactive state, AR is sequestered in the cytoplasm of cells by molecular chaperones. In the classical (genomic) AR signaling pathway, AR activation causes dissociation of the chaperones, AR dimerization and translocation to the nucleus to modulate gene expression. AR binds to the androgen response element (ARE) (Davey & Grossmann, 2016; Gao et al., 2005). Notably, for transcriptional regulation, the AR is closely associated with other co-factors that may differ between cells, tissues, and life stages. In this way, the functional consequence of AR activation is cell- and tissue-specific. This dependency on co-factors such as the SRC proteins also means that stressors affecting recruitment of co-activators to AR can result in decreased AR activity (Heinlein & Chang, 2002), as shown for the pyrethroid cypermethrin (Wang et al., 2016). Ligand-bound AR may also associate with cytoplasmic and membrane-bound proteins to initiate cytoplasmic signaling pathways with other functions than the nuclear pathway. Non-genomic AR signaling includes association with Src kinase to activate MAPK/ERK signaling and activation of the PI3K/Akt pathway. Decreased AR activation may therefore be a decrease in the genomic and/or non-genomic AR signaling pathways (Leung & Sadar, 2017).	
How it is Measured or Detected	
This KE specifically focuses on decreased <i>in vivo</i> activation, with most methods that can be used to measure AR activity carried out <i>in vitro</i>. They provide indirect information about the KE and are described in lower tier MIE/KEs (see for example MIE/KE-26 for AR antagonism, KE-1690 for decreased T levels, and KE-1613 for decreased dihydrotestosterone levels). Assays may in the future be developed to measure AR activation in mammalian organisms.	
References	
Davey, R. A., & Grossmann, M. (2016). Androgen Receptor Structure, Function and Biology: From Bench to Bedside. <i>The Clinical Biochemist. Reviews</i>, 37(1), 3–15. Gao, W., Bohl, C. E., & Dalton, J. T. (2005). Chemistry and structural biology of androgen receptor. <i>Chemical Reviews</i>, 105(9), 3352–3370. https://doi.org/10.1021/cr020456u Heinlein, C. A., & Chang, C. (2002). Androgen Receptor (AR) Coregulators: An Overview. https://academic.oup.com/edrv/article/23/2/175/2424160 Leung, J. K., & Sadar, M. D. (2017). Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. <i>Frontiers in Endocrinology</i>, 8. https://doi.org/10.3389/fendo.2017.00002 OECD (2022). Test No. 251: Rapid Androgen Disruption Activity Reporter (RADAR) assay. Paris: OECD Publishing doi:10.1787/da264d82-en. Wang Q, Zhou JL, Wang H, Ju Q, Ding Z, Zhou XL, Ge X, Shi QM, Pan C, Zhang JP, Zhang MR, Yu HM, Xu LC. (2016). Inhibition effect of cypermethrin mediated by co-regulators SRC-1 and SMRT in interleukin-6-induced androgen receptor activation. <i>Chemosphere</i>. 158:24-9. doi: 10.1016/j.chemosphere.2016.05.053	
Event: 286: Altered, Transcription of genes by the androgen receptor	
Short Name: Altered, Transcription of genes by the AR	

Event Component

Process	Object	Action
regulation of gene expression	androgen receptor	decreased

AOPs Including This Key Event

AOP ID and Name	Event Type
Aop:19 - Androgen receptor antagonism leading to adverse effects in the male fetus (mammals)	KeyEvent
Aop:307 - Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:344 - Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring	KeyEvent
Aop:345 - Androgen receptor (AR) antagonism leading to decreased fertility in females	KeyEvent
Aop:305 - 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:495 - Androgen receptor activation leading to prostate cancer	KeyEvent
Aop:306 - Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring	KeyEvent
Aop:496 - Androgen receptor agonism leading to reproduction dysfunction [in zebrafish]	KeyEvent
Aop:372 - Androgen receptor antagonism leading to testicular cancer	KeyEvent
Aop:570 - Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring	KeyEvent
Aop:571 - 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	KeyEvent
Aop:575 - Decreased testosterone synthesis leading to increased nipple retention (NR) in male (rodent) offspring	KeyEvent
Aop:576 - 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	KeyEvent
Aop:477 - Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring	KeyEvent

Stressors

Name
Bicalutamide
Cyproterone acetate
Epoxiconazole
Flutamide
Flusilazole
Prochloraz
Propiconazole
Stressor:286 Tebuconazole
Triticonazole
Vinclozalin

Biological Context**Level of Biological Organization**

Tissue

Domain of Applicability

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
During development and at adulthood	High

Sex Applicability

Sex	Evidence
Mixed	High

Both the DNA-binding and ligand-binding domains of the AR are highly evolutionary conserved, whereas the transactivation domain show more divergence, which may affect AR-mediated gene regulation across species (Davey and Grossmann 2016). Despite certain inter-species differences, AR function mediated through gene expression is highly conserved, with mutation studies from both humans and rodents showing strong correlation for AR-dependent development and function (Walters et al. 2010).

This KE is considered broadly applicable across mammalian taxa, sex, and developmental stages, as all mammals express the AR in numerous cells and tissues where it regulates gene transcription required for developmental processes and function. It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Description

This KE refers to transcription of genes by the androgen receptor (AR) as occurring in complex biological systems such as tissues and organs *in vivo*. Rather than measuring individual genes, this KE aims to capture patterns of effects at transcriptome level in specific target cells/tissues. In other words, it can be replaced by specific KEs for individual adverse outcomes as information becomes available, for example the transcriptional toxicity response in prostate tissue for AO: prostate cancer, perineum tissue for AO: reduced AGD, etc. AR regulates many genes that differ between tissues and life stages and, importantly, different gene transcripts within individual cells can go in either direction since AR can act as both transcriptional activator and suppressor. Thus, the 'directionality' of the KE cannot be either reduced or increased, but instead describe an altered transcriptome.

The Androgen Receptor and its function

The AR belongs to the steroid hormone nuclear receptor family. It is a ligand-activated transcription factor with three domains: the N-terminal domain, the DNA-binding domain, and the ligand-binding domain with the latter being the most evolutionary conserved (Davey and Grossmann 2016). Androgens (such as dihydrotestosterone and testosterone) are AR ligands and act by binding to the AR in androgen-responsive tissues (Davey and Grossmann 2016). Human AR mutations and mouse knockout models have established a fundamental role for AR in masculinization and spermatogenesis (Maclean et al.; Walters et al. 2010; Rana et al. 2014). The AR is also expressed in many other tissues such as bone, muscles, ovaries, and within the immune system (Rana et al. 2014).

Altered transcription of genes by the AR as a Key Event

Upon activation by ligand-binding, the AR translocates from the cytoplasm to the cell nucleus, dimerizes, binds to androgen response elements in the DNA to modulate gene transcription (Davey and Grossmann 2016). The transcriptional targets vary between cells and tissues, as well as with developmental stages and is also dependent on available co-regulators (Bevan and Parker 1999; Heemers and Tindall 2007). It should also be mentioned that the AR can work in other 'non-canonical' ways such as non-genomic signaling, and ligand-independent activation (Davey & Grossmann, 2016; Estrada et al, 2003; Jin et al, 2013).

A large number of known, and proposed, target genes of AR canonical signaling have been identified by analysis of gene expression following treatments with AR agonists (Bolton et al. 2007; Ngan et al. 2009, Jin et al. 2013).

How it is Measured or Detected

Altered transcription of genes by the AR can be measured by measuring the transcriptional level of known downstream target genes by RT-qPCR or other transcription analysis approaches, e.g. transcriptomics.

Since this KE aims to capture AR-mediated transcriptional patterns of effect, downstream bioinformatics analyses will typically be required to identify and compare effect footprints. Clusters of genes can be statistically associated with, for example, biological process terms or gene ontology terms relevant for AR-mediated signaling. Large transcriptomics data repositories

can be used to compare transcriptional patterns between chemicals, tissues, and species (e.g. TOXsIgN (Darde et al, 2018a; Darde et al, 2018b)), comparisons can be made to identify sets of AR 'biomarker' genes (e.g. as done in (Rooney et al, 2018)), and various methods can be used e.g. connectivity mapping (Keenan et al, 2019).

References

- Bevan C, Parker M (1999) The role of coactivators in steroid hormone action. *Exp. Cell Res.* 253:349–356
- Bolton EC, So AY, Chaivorapol C, et al (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. *Genes Dev* 21:2005–2017. doi: 10.1101/gad.1564207
- Darde, T. A., Gaudriault, P., Beranger, R., Lancien, C., Caillairec-Joly, A., Sallou, O., et al. (2018a). TOXsIgN: a cross-species repository for toxicogenomic signatures. *Bioinformatics* 34, 2116–2122. doi:10.1093/bioinformatics/bty040.
- Darde, T. A., Chalmel, F., and Svingen, T. (2018b). Exploiting advances in transcriptomics to improve on human-relevant toxicology. *Curr. Opin. Toxicol.* 11–12, 43–50. doi:10.1016/j.cotox.2019.02.001.
- Davey RA, Grossmann M (2016) Androgen Receptor Structure, Function and Biology: From Bench to Bedside. *Clin Biochem Rev* 37:3–15
- Estrada M, Espinosa A, Müller M, Jaimovich E (2003) Testosterone Stimulates Intracellular Calcium Release and Mitogen-Activated Protein Kinases Via a G Protein-Coupled Receptor in Skeletal Muscle Cells. *Endocrinology* 144:3586–3597. doi: 10.1210/en.2002-0164
- Heemers H V., Tindall DJ (2007) Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. *Endocr. Rev.* 28:778–808
- Jin, Hong Jian, Jung Kim, and Jindan Yu. 2013. "Androgen Receptor Genomic Regulation." *Translational Andrology and Urology* 2(3):158–77. doi: 10.3978/j.issn.2223-4683.2013.09.01
- Keenan, A. B., Wojciechowicz, M. L., Wang, Z., Jagodnik, K. M., Jenkins, S. L., Lachmann, A., et al. (2019). Connectivity Mapping: Methods and Applications. *Annu. Rev. Biomed. Data Sci.* 2, 69–92. doi:10.1146/ANNUREV-BIODATASCI-072018-021211.
- Maclean HE, Chu S, Warne GL, Zajack JD Related Individuals with Different Androgen Receptor Gene Deletions
- MacLeod DJ, Sharpe RM, Welsh M, et al (2010) Androgen action in the masculinization programming window and development of male reproductive organs. In: *International Journal of Andrology*. Blackwell Publishing Ltd, pp 279–287
- Ngan S, Stronach EA, Photiou A, et al (2009) Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. *Oncogene* 28:2051–2063. doi: 10.1038/onc.2009.68
- Rana K, Davey RA, Zajack JD (2014) Human androgen deficiency: Insights gained from androgen receptor knockout mouse models. *Asian J. Androl.* 16:169–177
- Rooney, J. P., Chorley, B., Kleinstreuer, N., and Corton, J. C. (2018). Identification of Androgen Receptor Modulators in a Prostate Cancer Cell Line Microarray Compendium. *Toxicol. Sci.* 166, 146–162. doi:10.1093/TOXSCI/KFY187.
- Walters KA, Simanainen U, Handelsman DJ (2010) Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. *Hum Reprod Update* 16:543–558. doi: 10.1093/humupd/dmq003

List of Adverse Outcomes in this AOP

Event: 2082: Hypospadias, increased

Short Name: Hypospadias

Event Component

Process	Object	Action
embryonic organ development	penis	abnormal

AOPs Including This Key Event

AOP ID and Name	Event Type
Aop:477 - Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring	AdverseOutcome

AOP ID and Name	Event Type
Aop:527 - Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) leads to Hypospadias, increased	AdverseOutcome
Aop:570 - Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring	AdverseOutcome
Aop:571 - 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	AdverseOutcome

Biological Context

Level of Biological Organization

Organ

Organ term

Organ term

penis

Domain of Applicability

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
human	Homo sapiens	High	NCBI
mouse	Mus musculus	High	NCBI
rat	Rattus norvegicus	High	NCBI
mammals	mammals		NCBI

Life Stage Applicability

Life Stage Evidence

Perinatal High

Sex Applicability

Sex Evidence

Male High

Taxonomic applicability: Several studies have shown an association in humans between *in utero* exposure to endocrine disrupting chemicals and hypospadias (Baskin et al., 2001; Kalfa et al., 2015; Mattiske & Pask, 2021). In mice and rats, *in utero* exposure to several endocrine disrupting chemicals, in particular estrogens and anti-androgens, have been shown to cause hypospadias in male offspring at different frequencies (Mattiske & Pask, 2021). Androgen-driven development of the male external genitalia is evolutionary conserved in most mammals and, to some extent, also in other vertebrate classes (Gredler et al., 2014). Hypospadias can in principle occur in all animals that form a genital tubercle and have been observed in many domestic animal species and wildlife species.

Life stage applicability: Penis development is finished prenatally in humans, and hypospadias is diagnosed at birth (Baskin & Ebbers, 2006). In rodents, penis development is not fully completed until weeks after birth, but hypospadias may be identified in early postnatal life as well, and in some cases in late gestation (Sinclair et al., 2017).

Sex applicability: Hypospadias is primarily used in reference to malformation of the male external genitalia.

Key Event Description

Hypospadias is a malformation of the penis where the urethral opening is displaced from the tip of the glans, usually on the ventral side on the penis. Most cases of hypospadias are milder where the urethral opening still appears on the glans proper or on the most distal part of the shaft. In more severe cases, the opening may be more proximally placed on the shaft or even as low as the scrotum or the perineum.

In addition to the misplacement of the urethral opening, hypospadias is associated with an absence of ventral prepuce, an excess of dorsal preputial tissue, and in some cases a downward curvature of the penis (chordee). Patients with hypospadias may need surgical repairment depending on severity, with more proximal hypospadias patients in most need of surgeries to achieve optimal functional and cosmetic results (Baskin, 2000; Baskin & Ebbers, 2006; Mattiske & Pask, 2021). The prevalence

of hypospadias varies greatly between countries, from 1:100 to 1:500 of newborn boys (Skakkebaek et al., 2016). Several studies report increases in hypospadias prevalence, though these trends are country- and region-specific with high variability between studies (Paulozzi, 1999; Springer et al., 2016; Yu et al., 2019).

The external genitalia arise from the biphasic genital tubercle during fetal development. Androgens (testosterone and dihydrotestosterone) drive formation of the male external genitalia. In humans, the urethra develops by fusion of two endoderm-derived urethral folds. Disruption of genital tubercle differentiation results in an incomplete urethra, i.e. hypospadias. (Baskin, 2000; Baskin & Ebbers, 2006).

How it is Measured or Detected

In humans, hypospadias is diagnosed clinically by physical examination of the infant and is at first recognized by the absence of ventral prepuce and concurrent excess dorsal prepuce (Baskin, 2000). Hypospadias may be classified according to the location of the urethral meatus: Glandular, subcoronal, midshaft, penoscrotal, scrotal, and perineal (Baskin & Ebbers, 2006).

In mice and rats, macroscopic assessment of hypospadias may be performed postnatally, and several OECD test guidelines (TG) require macroscopic examination of genital abnormalities in *in vivo* toxicity studies (TG 414, 416, 421/422, 443). The guidelines do not define hypospadias or how to identify them. Fetal and neonatal identification of hypospadias may require microscopic examination for proper evaluation of the pathology. This can be done by scanning electron microscopy (Uda et al., 2004), or by histological assessment in which the presence of the urethral opening in proximal, transverse sections (for example co-occurring with the os penis or corpus cavernosum) indicates hypospadias (Mahawong et al., 2014; Sinclair et al., 2017; Vilela et al., 2007). In a semiquantitative, histological approach, the number of transverse sections of the penis with internalization of the urethra was related to the total length of the penis, achieving a percentage of urethral internalization. In this study, $\leq 89\%$ of urethral internalization was defined as indicative of mild hypospadias (Stewart et al., 2018).

Regulatory Significance of the AO

In the OECD guidelines for developmental and reproductive toxicology, several test endpoints include examination of structural abnormalities with special attention to the organs of the reproductive system. These are: Test No. 414 'Prenatal Developmental Toxicity Study' (OECD, 2018a); Test No. 416 'Two-Generation Reproduction Toxicity' (OECD, 2001) and Tests No. 421/422 'Reproduction/Developmental Toxicity Screening Test' (OECD, 2016a, 2016b). In Test No. 443 'Extended One-Generation Reproductive Toxicity Study' (OECD, 2018b), hypospadias is specifically mentioned as a genital abnormality to note.

References

- Baskin, L., Himes, K., & Colborn, T. (2001). Hypospadias and Endocrine Disruption: Is There a Connection? *Environmental Health Perspectives*, 109(11), 1175–1183. <http://ehpnet1.niehs.nih.gov/docs/2001/109p1175-1183baskin/abstract.html>
- Baskin, L. S. (2000). Hypospadias and urethral development. *The Journal of Urology*, 163(3), 951–956.
- Baskin, L. S., & Ebbers, M. B. (2006). Hypospadias: Anatomy, etiology, and technique. *Journal of Pediatric Surgery*, 41(3), 463–472. <https://doi.org/10.1016/j.jpedsurg.2005.11.059>
- Gredler, M. L., Larkins, C. E., Leal, F., Lewis, A. K., Herrera, A. M., Perriton, C. L., Sanger, T. J., & Cohn, M. J. (2014). Evolution of External Genitalia: Insights from Reptilian Development. *Sexual Development*, 8(5), 311–326. <https://doi.org/10.1159/000365771>
- Kalfa, N., Paris, F., Philibert, P., Orsini, M., Broussous, S., Fauconnet-Servant, N., Audran, F., Gaspari, L., Lehors, H., Haddad, M., Guys, J. M., Reynaud, R., Alessandrini, P., Merrot, T., Wagner, K., Kurzenne, J. Y., Bastiani, F., Bréaud, J., Valla, J. S., ... Sultan, C. (2015). Is Hypospadias Associated with Prenatal Exposure to Endocrine Disruptors? A French Collaborative Controlled Study of a Cohort of 300 Consecutive Children Without Genetic Defect. *European Urology*, 68(6), 1023–1030. <https://doi.org/10.1016/j.eururo.2015.05.008>
- Mahawong, P., Sinclair, A., Li, Y., Schlomer, B., Rodriguez, E., Ferretti, M. M., Liu, B., Baskin, L. S., & Cunha, G. R. (2014). Prenatal diethylstilbestrol induces malformation of the external genitalia of male and female mice and persistent second-generation developmental abnormalities of the external genitalia in two mouse strains. *Differentiation*, 88(2–3), 51–69. <https://doi.org/10.1016/j.diff.2014.09.005>
- Mattiske, D. M., & Pask, A. J. (2021). Endocrine disrupting chemicals in the pathogenesis of hypospadias; developmental and toxicological perspectives. *Current Research in Toxicology*, 2, 179–191. <https://doi.org/10.1016/j.crttox.2021.03.004>
- OECD. (2001). Test No. 416: Two-Generation Reproduction Toxicity. In *OECD Guidelines for the Testing of Chemicals, Section 4* OECD Publishing. <https://doi.org/10.1787/9789264070868-en>
- OECD. (2018). Test No. 414: Prenatal Developmental Toxicity Study. In *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing. <https://doi.org/10.1787/9789264070820-en>
- OECD. (2025a). Test No. 421: Reproduction/Developmental Toxicity Screening Test. In *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing. <https://doi.org/doi.org/10.1787/9789264264380-en>
- OECD. (2025b). Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity

Screening Test. In *OECD Guidelines for the Testing of Chemicals, Section 4* OECD Publishing. <https://doi.org/doi.org/10.1787/9789264264403-en>

OECD. (2025c). Test No. 443: Extended One-Generation Reproductive Toxicity Study. In *OECD Guidelines for the Testing of Chemicals, Section 4*. OECD Publishing. <https://doi.org/doi.org/10.1787/9789264185371-en>

Paulozzi, L. J. (1999). International Trends in Rates of Hypospadias and Cryptorchidism. *Environmental Health Perspectives*, 107(4), 297–302. <https://doi.org/10.1289/ehp.99107297>

Sinclair, A. W., Cao, M., Pask, A., Baskin, L., & Cunha, G. R. (2017). Flutamide-induced hypospadias in rats: A critical assessment. *Differentiation*, 94, 37–57. <https://doi.org/10.1016/j.diff.2016.12.001>

Skakkebaek, N. E., Rajpert-De Meyts, E., Buck Louis, G. M., Toppari, J., Andersson, A.-M., Eisenberg, M. L., Jensen, T. K., Jørgensen, N., Swan, S. H., Sapra, K. J., Ziebe, S., Priskorn, L., & Juul, A. (2016). Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility. *Physiological Reviews*, 96(1), 55–97. <https://doi.org/10.1152/physrev.00017.2015.-lt>

Springer, A., van den Heijkant, M., & Baumann, S. (2016). Worldwide prevalence of hypospadias. *Journal of Pediatric Urology*, 12(3), 152.e1–152.e7. <https://doi.org/10.1016/j.jpuro.2015.12.002>

Stewart, M. K., Mattiske, D. M., & Pask, A. J. (2018). In utero exposure to both high- and low-dose diethylstilbestrol disrupts mouse genital tubercle development. *Biology of Reproduction*, 99(6), 1184–1193. <https://doi.org/10.1093/biolre/joy142>

Uda, A., Kojima, Y., Hayashi, Y., Mizuno, K., Asai, N., & Kohri, K. (2004). Morphological features of external genitalia in hypospadiac rat model: 3-dimensional analysis. *The Journal of Urology*, 171(3), 1362–1366. <https://doi.org/10.1097/01.JU.0000100140.42618.54>

Vilela, M. L. B., Willingham, E., Buckley, J., Liu, B. C., Agras, K., Shiroyanagi, Y., & Baskin, L. S. (2007). Endocrine Disruptors and Hypospadias: Role of Genistein and the Fungicide Vinclozolin. *Urology*, 70(3), 618–621. <https://doi.org/10.1016/j.urology.2007.05.004>

Yu, X., Nassar, N., Mastroiacovo, P., Canfield, M., Groisman, B., Bermejo-Sánchez, E., Ritvanen, A., Kiuru-Kuhlefelt, S., Benavides, A., Sipek, A., Pierini, A., Bianchi, F., Källén, K., Gatt, M., Morgan, M., Tucker, D., Canessa, M. A., Gajardo, R., Mutchinick, O. M., ... Agopian, A. J. (2019). Hypospadias Prevalence and Trends in International Birth Defect Surveillance Systems, 1980–2010. *European Urology*, 76(4), 482–490. <https://doi.org/10.1016/j.eururo.2019.06.027>

Appendix 2

List of Key Event Relationships in the AOP

List of Adjacent Key Event Relationships

Relationship: 1880: Inhibition, 5 α -reductase leads to Decrease, DHT level

AOPs Referencing Relationship

AOP Name	Adjacency	Weight of Evidence	Quantitative Understanding
Inhibition of 5α-reductase leading to impaired fecundity in female fish	adjacent	High	High
5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	adjacent	High	High
5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	adjacent	High	
5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	adjacent	High	

Evidence Supporting Applicability of this Relationship

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
------------	----------

Life Stage

During development and at adulthood

Evidence

High

Sex Applicability**Sex Evidence**

Mixed High

This KE is applicable for both sexes, across developmental stages into adulthood, in numerous cells and tissues, and across mammalian taxa. It is, however, acknowledged that this KER most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Relationship Description

This key event relationship (KER) links inhibition of 5 α -reductase activity to decreased dihydrotestosterone (DHT) levels.

There are three isozymes of 5 α -reductase: type 1, 2, and 3. 5 α -reductase type 2 is mainly involved in the synthesis of 5 α -DHT from testosterone (T) (Robitaille & Langlois, 2020), although 5 α -reductase type 1 can also facilitate this reaction, but with lower affinity for T (Nikolaou et al., 2021). The type 1 isoform is also involved in the alternative ('backdoor') pathway for DHT formation, facilitating the conversion of progesterone or 17OH-progesterone to dihydroprogesterone or 5 α -pregnan-17 α -ol-3,20-dione, respectively, whereafter several subsequent reactions will ultimately lead to the formation of DHT (Miller & Auchus, 2019). The quantitative importance of the alternative pathway remains unclear (Alemany, 2022). The type 1 and type 2 isoforms of 5 α -reductase are the primary focus of this KER.

The direct conversion of T to 5 α -DHT mainly takes place in the target tissue (Robitaille & Langlois, 2020). In mammals, the type 1 isoform is found in the scalp and other peripheral tissues (Miller & Auchus, 2011), such as liver, skin, prostate (Azzouni et al., 2012), bone, ovaries, and adipose tissue (Nikolaou et al., 2021). The type 2 isoform is expressed mainly in male reproductive tissues (Miller & Auchus, 2011), but also in liver, scalp, and skin (Nikolaou et al., 2021). The expression level of both isoforms depend on the developmental stage and the tissue.

Evidence Supporting this KER**Biological Plausibility**

The biological plausibility of this KER is considered high.

5 α -reductase can catalyze the conversion of T to DHT. The substrates for 5 α -reductases are 3-oxo (3-keto), Δ^4 ,⁵ C19/C21 steroids such as testosterone and progesterone. The enzymatic reaction leads to an irreversible breakage of the double bond between carbon 4 and 5 and subsequent insertion of a hydride anion at carbon 5 and insertion of a proton at carbon 4. The reaction is aided by the cofactor NADPH (Azzouni et al., 2012). By inhibiting this enzyme, the described catalyzed reaction will be inhibited, leading to a decrease in DHT levels.

In both humans and rodents, DHT is important for the *in utero* differentiation and growth of the prostate and male external genitalia. Besides its critical role during fetal development, DHT also induces growth of facial and body hair during puberty in humans (Azzouni et al., 2012).

Empirical Evidence

The empirical evidence for this KER is considered high

Dose concordance

Several inhibitors of 5 α -reductases have been developed for pharmacological uses. Inhibition of the enzymatic conversion of radiolabeled substrate has been illustrated (Table 1) and data display dose-concordance, with increasing concentrations of inhibitor leading to lower 5 α -reductase product formation. These studies at large rely on conversion of radiolabeled substrate and hence serve as indirect measurements.

Table 1: Dose concordance from selected in vitro test systems

Test system	Model description	Stressor	Effect	Reference
-------------	-------------------	----------	--------	-----------

HEK-293 cells	Cells stably transfected human 5 α -reductase type 1 and 2 used to measure conversion of [¹⁴ C]labeled steroids	Finasteride	Type 1: IC ₅₀ = 106.9 μ M Type 2: IC ₅₀ = 14.3 μ M	(Yamana et al., 2010)
		Dutasteride	Type 1: IC ₅₀ = 8.7 μ M Type 2: IC ₅₀ = 57 μ M	
COS cells	Cell homogenates from transfected cells with human and rat 5 α -reductase (unknown isoform) used to measure conversion of radiolabeled testosterone	Finasteride	Human: IC ₅₀ $\approx$ 1 μ M K _i = 340-620 nM Rat: IC ₅₀ $\approx$ 0.1 μ M K _i = 3-5 nM	(Andersson & Russell, 1990)
		4-MA	Human: IC ₅₀ $\approx$ 0.1 μ M K _i = 7-8 nM Rat: IC ₅₀ $\approx$ 0.1 μ M K _i = 5-7 nM	
CHO cells	Stably transfected with human 5 α -reductase type 1 and 2	Finasteride	Type 1: K _i = 325 nM Type 2: K _i = 12 nM	(Thigpens et al., 1993)
		4-MA	Type 1: K _i = 8 nM Type 2: K _i = 4 nM	
Isolated enzyme	Human 5 α -reductase type 1 and 2 used to measure conversion of radiolabeled substrate of both isoforms	Finasteride	Type 1: K _i = > 200 nM Type 2: K _i = 0.45 nM	(Peng et al., 2020)
		Dutasteride	Type 1: K _i = 39 nM Type 2: K _i = 1.1 nM	

These *in vitro* studies clearly show effects on the enzymatic reaction induced by 5 α -reductases in a concentration dependent manner (Andersson & Russell, 1990; Thigpens et al., 1993; Yamana et al., 2010).

In the intact organism, when 5 α -reductase type 2 activity is lacking through e.g. inhibitor treatment or knockout, this will result in decreased 5 α -DHT locally in the tissues, but also in blood (Robitaille & Langlois, 2020). This has been demonstrated in humans, rats, monkeys, and mice (Robitaille et al. 2020).

Finasteride is a specific inhibitor of 5 α -reductase type 2 (Russell & Wilson, 1994). Men with androgenic alopecia were treated with increasing concentrations of finasteride and presented with decreased DHT levels in biopsies from scalp, as well as a decrease in serum DHT levels with dose dependency being most apparent in serum, up to about 70% decrease (Drake et al., 1999). Likewise, men treated with dutasteride exhibited a clear dose-dependent decrease in serum DHT after 24 weeks treatment with a maximum efficacy of about 98% (Clark et al., 2004).

Other evidence

Males with deficiency in 5 α -reductases are typically born with ambiguous external genitalia. They also present with small prostate, minimal facial hair and acne, or temporal hair loss. Comparison of affected individuals to non-affected

individuals in regard to T/DHT ratio, conversion of infused radioactive T, and ratios of urinary metabolites of 5 α -reductase and 5 β -reductase concluded that these phenotypic characteristics were due to 5 α -reductase defects that resulted in less conversion of T to DHT (Okeigwe et al. 2014). Mutations in the 5 α -reductase gene can result in boys being born with moderate to severe undervirilization phenotypes (Elzenaty 2022).

Quantitative Understanding of the Linkage

Inhibitors of 5 α -reductase are important for the prevention and treatment of many diseases. There are several compounds that have been developed for pharmaceutical purposes and they can target the different isoforms with different affinity. Examples of inhibitors are finasteride and dutasteride. Finasteride mainly has specificity for the type 2 isoform, whereas dutasteride inhibits both type 1 and 2 isoforms (Miller & Auchus, 2011).

These differences in isoform specificity reflects in the effects on DHT serum levels, hence the broader specificity of dutasteride leads to > 90% decrease in patients with benign prostatic hyperplasia, in comparison to 70% with finasteride administration (Nikolaou et al., 2021).

Response-response relationship

Enzyme inhibition can occur in different ways e.g. both competitive and non-competitive. The inhibition model depends on the specific inhibitor and hence a generic quantitative response-response relationship is difficult to derive.

Time-scale

An inhibition of 5 α -reductases would lead to an immediate change in DHT levels at the molecular level. However, the time-scale for systemic effects on hormone levels are challenging to estimate.

Known Feedforward/Feedback loops influencing this KER

Androgens can regulate gene expression of 5 α -reductases (Andersson et al., 1989; Berman & Russell, 1993).

References

- Alemamy, M. (2022). The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health. In *International Journal of Molecular Sciences* (Vol. 23, Issue 19). MDPI. <https://doi.org/10.3390/ijms231911952>
- Andersson, S., Bishop, R. W., & Russell, D. W. (1989). *THE JOURNAL OF BIOLOGICAL CHEMISTRY Expression Cloning and Regulation of Steroid 5 α -Reductase, an Enzyme Essential for Male Sexual Differentiation** (Vol. 264, Issue 27).
- Andersson, S., & Russell, D. W. (1990). Structural and biochemical properties of cloned and expressed human and rat steroid 5 α -reductases. *Proc. Natl. Acad. Sci. USA*, 87, 3640–3644. <https://www.pnas.org>
- Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012). The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. In *Advances in Urology*. <https://doi.org/10.1155/2012/530121>
- Berman, D. M., & Russell, D. W. (1993). Cell-type-specific expression of rat steroid 5 α -reductase isozymes (sexual development/androgens/prostate/stroma/epithelium). In *Proc. Natl. Acad. Sci. USA* (Vol. 90). <https://www.pnas.org>
- Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5 α -Reductase Inhibitor. *Journal of Clinical Endocrinology and Metabolism*, 89(5), 2179–2184. <https://doi.org/10.1210/jc.2003-030330>
- Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W. P., Cotterill, P. C., Thiboutot, D. M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S. J., Griffin, E. I., Weiss, D., Carrington, P., Gencheff, C., Cole, G. W., Pariser, D. M., Epstein, E. S., ... City, O. (1999). *The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia*
- Miller, W. L., & Auchus, R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocrine Reviews*, 32(1), 81–151. <https://doi.org/10.1210/er.2010-0013>
- Miller, W. L., & Auchus, R. J. (2019). The “backdoor pathway” of androgen synthesis in human male sexual development. *PLoS Biology*, 17(4). <https://doi.org/10.1371/journal.pbio.3000198>
- Nikolaou, N., Hodson, L., & Tomlinson, J. W. (2021). The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies. In *Journal of Steroid Biochemistry and Molecular Biology* (Vol. 207). Elsevier Ltd. <https://doi.org/10.1016/j.jsbmb.2021.105808>
- Peng, H. M., Valentin-Goyco, J., Im, S. C., Han, B., Liu, J., Qiao, J., & Auchus, R. J. (2020). Expression in escherichia coli, purification, and functional reconstitution of human steroid 5 α -reductases. *Endocrinology (United States)*, 161(8), 1–11. <https://doi.org/10.1210/ENDOCR/BQAA117>
- Robitaille, J., & Langlois, V. S. (2020). Consequences of steroid-5 α -reductase deficiency and inhibition in vertebrates. In *General and Comparative Endocrinology* (Vol. 290). Academic Press Inc. <https://doi.org/10.1016/j.ygcen.2020.113400>
- Russell, D. W., & Wilson, J. D. (1994). *STEROID 5 α -REDUCTASE: TWO GENES/TWO ENZYMES*. www.annualreviews.org
- Thigpens, A. E., Cala, K. M., & Russell, D. W. (1993). Characterization of Chinese Hamster Ovary Cell Lines Expressing Human

Steroid 5 α -Reductase Isozymes. *The Journal of Biological Chemistry*, 268(23), 17404–17412.

Yamana, K., Fernand, L., Luu-The, V., & Luu-The, V. (2010). Human type 3 5 α -reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. *Hormone Molecular Biology and Clinical Investigation*, 2(3), 293–299. <https://doi.org/10.1515/HMBCI.2010.035>

Relationship: 1935: Decrease, DHT level leads to Decrease, AR activation

AOPs Referencing Relationship

AOP Name	Adjacency	Weight of Evidence	Quantitative Understanding
Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)	adjacent	High	High
5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	adjacent	High	
5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	adjacent	High	
5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	adjacent	High	

Evidence Supporting Applicability of this Relationship

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
During development and at adulthood	High

Sex Applicability

Sex	Evidence
Mixed	High

Taxonomic applicability

KER-1935 is assessed applicable to mammals, as DHT and AR activation are known to be related in mammals. It is, however, acknowledged that this KER most likely has a much broader domain of applicability, extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Sex applicability

KER-1935 is assessed applicable to both sexes, as DHT activates AR in both males and females.

Life-stage applicability

KER-1935 is considered applicable to developmental and adult life stages, as DHT-mediated AR activation is relevant when the AR is expressed.

Key Event Relationship Description

Dihydrotestosterone (DHT) is a primary ligand for the Androgen receptor (AR), a nuclear receptor and transcription factor. DHT is an endogenous sex hormone that is synthesized from e.g. testosterone by the enzyme 5 α -reductase in different tissues and organs ([Davey & Grossmann, 2016](#); [Marks, 2004](#)). In the absence of ligand (e.g. DHT) the AR is localized in the cytoplasm in complex with molecular chaperones. Upon ligand binding, AR is activated, translocated into the nucleus, and dimerizes to carry out its 'genomic function' ([Davey & Grossmann, 2016](#)). Hence, AR transcriptional function is directly dependent on the presence of ligands, with DHT being a more potent AR activator than testosterone ([Grino et al, 1990](#)). Reduced levels of DHT may thus lead to reduced AR activation. Besides its genomic actions, the AR can also mediate rapid, non-genomic second messenger signaling ([Davey and Grossmann, 2016](#)). Decreased DHT levels that lead to reduced AR activation can thus entail downstream effects on both genomic and non-genomic signaling.

Evidence Supporting this KER

Biological Plausibility

The biological plausibility of KER1935 is considered high.

The activation of AR is dependent on binding of ligands (though a few cases of ligand-independent AR activation has been shown, see *uncertainties and inconsistencies*), primarily testosterone and DHT in mammals (Davey and Grossmann, 2016; Schuppe et al., 2020). Without ligand activation, the AR will remain in the cytoplasm associated with heat-shock and other chaperones and not be able to carry out its canonical ('genomic') function. Upon androgen binding, the AR undergoes a conformational change, chaperones dissociate, and a nuclear localization signal is exposed. The androgen/AR complex can now translocate to the nucleus, dimerize and bind AR response elements to regulate target gene expression (Davey and Grossmann, 2016; Eder et al., 2001). AR transcriptional activity and specificity is regulated by co-activators and co-repressors in a cell-specific manner (Heinlein and Chang, 2002).

The requirement for androgens binding to the AR for transcriptional activity has been extensively studied and proven and is generally considered textbook knowledge. The OECD test guideline no. 458 uses DHT as the reference chemical for testing androgen receptor activation *in vitro* (OECD, 2020). In the absence of DHT during development caused by 5 α -reductase deficiency (i.e. still in the presence of testosterone), male fetuses fail to masculinize properly. This is evidenced by, for instance, individuals with congenital 5 α -reductase deficiency conditions (Costa et al., 2012); conditions not limited to humans (Robitaille and Langlois, 2020), testifying to the importance of specifically DHT for AR activation and subsequent masculinization of certain reproductive tissues.

Binding of testosterone or DHT has differential effects in different tissues. E.g. in the developing mammalian male, testosterone is required for development of the internal sex organs (epididymis, vas deferens, and the seminal vesicles), whereas DHT is crucial for development of the external sex organs (Keller et al., 1996; Robitaille and Langlois, 2020).

Empirical Evidence

The empirical support for KER1935 is considered high.

Dose concordance:

- Increasing concentrations of DHT lead to increasing AR activation *in vitro* in AR reporter gene assays (OECD, 2020; Williams et al., 2017).

Indirect (supporting) evidence:

- In cell lines where proliferation can be induced by androgens (such as prostate cancer cells), proliferation can be used as a readout for AR activation. Finasteride, a 5 α -reductase inhibitor, dose-dependently decreases AR-mediated prostate cancer cell line proliferation (Bologna et al., 1995). 0.001 μ M finasteride decreased the growth rate with 44%, 0.1 μ M decreased the growth rate with 80%.
- Specific events of masculinization during development are dependent on AR activation by DHT, including the development and length of the perineum which can be measured as the anogenital distance (AGD, (Schwartz et al., 2019)). E.g. a dose-dependent effect of rat *in utero* exposure to the 5 α -reductase inhibitor finasteride was observed on the length of the AGD, where 0.01 mg/kg bw/day finasteride reduced the AGD measured at pup day 1 by 8%, whereas 1 mg/kg bw/day reduced the AGD by 23% (Bowman et al., 2003).

Other evidence:

- Male individuals with congenital 5 α -reductase deficiency (absence of DHT) fail to masculinize properly (Costa et al., 2012).
- A major driver of prostate cancer growth is AR activation (Davey and Grossmann, 2016; Huggins and Hodges, 1941). Androgen deprivation is used as treatment including 5 α -reductase inhibitors to reduce DHT levels (Aggarwal et al., 2010).

Uncertainties and Inconsistencies

Ligand-independent actions of the AR have been identified. To what extent and of which biological consequences is not well defined (Bennesch and Picard, 2015).

It should be noted that in tissues that are not DHT-dependent but rather respond to T, a decrease in DHT level may not influence AR activation significantly in that specific tissue.

Quantitative Understanding of the Linkage

Response-response relationship

There is a positive dose-response relationship between increasing concentrations of DHT and AR activation (Dalton et al., 1998; OECD, 2020). However, there is not enough data, or overview of the data, to define a quantitative linkage *in vivo*, and such a relationship will differ between biological systems (species, tissue, cell type).

Time-scale

Upon DHT binding to the AR, a conformational change that brings the amino (N) and carboxy (C) termini into close proximity

occurs with a $t_{1/2}$ of approximately 3.5 minutes, around 6 minutes later, the AR dimerizes as shown in transfected HeLa cells (Schaufele et al., 2005). Addition of 5 nM DHT to the culture medium of 'AR-resistant' transfected prostatic cancer cells resulted in a rapid (from 15 minutes, maximal at 30 minutes) nuclear translocation of the AR with minimal residual cytosolic expression (Nightingale et al., 2003). AR and promoter interactions occur within 15 minutes of ligand binding, and RNA polymerase II and coactivator recruitment are then proposed to occur transiently with cycles of approximately 90 minutes (Kang et al., 2002).

Known modulating factors

Modulating Factor (MF)	MF Specification	Effect(s) on the KER	Reference(s)
Age	AR expression changes with aging	Tissue-specific alterations in AR activity with aging	(Supakar et al., 1993; Wu et al., 2009)
Genotype	Number of CAG repeats in the first exon of AR	Decreased AR activation with increased number of CAGs	(Chamberlain et al., 1994; Tut et al., 1997)
Androgen deficiency syndrome	Low circulating testosterone levels due to primary (testicular) or secondary (pituitary-hypothalamic) hypogonadism	Reduced levels of circulating testosterone, precursor of DHT	(Bhasin et al., 2010)
Castration	Removal of testicles	Reduced levels of circulating testosterone, precursor of DHT	(Krotkiewski et al., 1980)

Known Feedforward/Feedback loops influencing this KER

Androgens have been shown to upregulate and downregulate AR expression as well as 5 α -reductase expression, but for 5 α -reductase, each isoform in each tissue is differently regulated by androgens and can display sexual dimorphism (Lee and Chang, 2003; Robitaille and Langlois, 2020). The quantitative impact of such adaptive expression changes is unknown.

References

- Aggarwal, S., Thareja, S., Verma, A., Bhardwaj, T.R., Kumar, M., 2010. An overview on 5 α -reductase inhibitors. *Steroids* 75, 109–153. <https://doi.org/10.1016/j.steroids.2009.10.005>
- Bennesch, M.A., Picard, D., 2015. Minireview: Tipping the Balance: Ligand-Independent Activation of Steroid Receptors. *Mol. Endocrinol.* 29, 349–363. <https://doi.org/10.1210/ME.2014-1315>
- Bhasin, S., Cunningham, G.R., Hayes, F.J., Matsumoto, A.M., Snyder, P.J., Swerdloff, R.S., Montori, V.M., 2010. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol. Metab.* 95, 2536–2559. <https://doi.org/10.1210/JC.2009-2354>
- Bologna, M., Muzi, P., Biordi, L., Festuccia, C., Vicentini, C., 1995. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. *Urology* 45, 282–290. [https://doi.org/10.1016/0090-4295\(95\)80019-0](https://doi.org/10.1016/0090-4295(95)80019-0)
- Bowman, C.J., Barlow, N.J., Turner, K.J., Wallace, D.G., Foster, P.M.D., 2003. Effects of in Utero Exposure to Finasteride on Androgen-Dependent Reproductive Development in the Male Rat. *Toxicol. Sci.* 74, 393–406. <https://doi.org/10.1093/TOXSCI/KFG128>
- Chamberlain, N.L., Driver, E.D., Miesfeld, R.L., 1994. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Res.* 22, 3181. <https://doi.org/10.1093/NAR/22.15.3181>
- Costa, E.F., Domenice, S., Sircili, M., Inacio, M., Mendonca, B., 2012. DSD due to 5 α -reductase 2 deficiency - From diagnosis to long term outcome. *Semin. Reprod. Med.* 30, 427–431. <https://doi.org/10.1055/S-0032-1324727/ID/JR00766-20/BIB>
- Dalton, J.T., Mukherjee, A., Zhu, Z., Kirkovsky, L., Miller, D.D., 1998. Discovery of nonsteroidal androgens. *Biochem. Biophys. Res. Commun.* 244, 1–4. <https://doi.org/10.1006/bbrc.1998.8209>
- Davey, R.A., Grossmann, M., 2016. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. *Clin. Biochem. Rev.* 37, 3–15.
- Eder, I.E., Culig, Z., Putz, T., Nessler-Menardi, C., Bartsch, G., Klocker, H., 2001. Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic. *Eur. Urol.* 40, 241–251. <https://doi.org/10.1159/000049782>
- Grino, P.B., Griffin, J.E., Wilson, J.D., 1990. Testosterone at High Concentrations Interacts with the Human Androgen Receptor Similarly to Dihydrotestosterone. *Endocrinology* 126, 1165–1172. <https://doi.org/10.1210/endo-126-2-1165>
- Heinlein, C.A., Chang, C., 2002. Androgen Receptor (AR) Coregulators: An Overview. *Endocr. Rev.* 23, 175–200. <https://doi.org/10.1210/EDRV.23.2.0460>

- Huggins, C., Hodges, C. V., 1941. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res.* 1, 293-297.
- Kang, Z., Pirskanen, A., Jänne, O.A., Palvimo, J.J., 2002. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. *J. Biol. Chem.* 277, 48366-48371. <https://doi.org/10.1074/jbc.M209074200>
- Keller, E.T., Ershler, W.B., Chang, C., 1996. The androgen receptor: a mediator of diverse responses. *Front. Biosci. (Landmark Ed)* 1, 59-71. <https://doi.org/10.2741/A116>
- Krotkiewski, M., Kral, J.G., Karlsson, J., 1980. Effects of castration and testosterone substitution on body composition and muscle metabolism in rats. *Acta Physiol. Scand.* 109, 233-237. <https://doi.org/10.1111/j.1748-1716.1980.tb06592.x>
- Lee, D.K., Chang, C., 2003. Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication. *J. Clin. Endocrinol. Metab.* 88, 4043-4054. <https://doi.org/10.1210/jc.2003-030261>
- Marks, L.S., 2004. 5Alpha-Reductase: History and Clinical Importance. *Rev. Urol.* 6 Suppl 9, S11-21.
- Nightingale, J., Chaudhary, K.S., Abel, P.D., Stubbs, A.P., Romanska, H.M., Mitchell, S.E., Stamp, G.W.H., Lalani, E.N., 2003. Ligand Activation of the Androgen Receptor Downregulates E-Cadherin-Mediated Cell Adhesion and Promotes Apoptosis of Prostatic Cancer Cells. *Neoplasia* 5, 347. [https://doi.org/10.1016/S1476-5586\(03\)80028-3](https://doi.org/10.1016/S1476-5586(03)80028-3)
- OECD, 2020. Test No. 458: Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist Activity of Chemicals, OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. <https://doi.org/10.1787/9789264264366-en>
- Robitaille, J., Langlois, V.S., 2020. Consequences of steroid-5 α -reductase deficiency and inhibition in vertebrates. *Gen. Comp. Endocrinol.* 290. <https://doi.org/10.1016/j.ygcen.2020.113400>
- Schaufele, F., Carbonell, X., Guerbardot, M., Borngraeber, S., Chapman, M.S., Ma, A.A.K., Miner, J.N., Diamond, M.I., 2005. The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions. *Proc. Natl. Acad. Sci. U. S. A.* 102, 9802-9807. <https://doi.org/10.1073/pnas.0408819102>
- Schuppe, E.R., Miles, M.C., Fuxjager, M.J., 2020. Evolution of the androgen receptor: Perspectives from human health to dancing birds. *Mol. Cell. Endocrinol.* 499, 110577. <https://doi.org/10.1016/j.mce.2019.110577>
- Schwartz, C.L., Christiansen, S., Vinggaard, A.M., Axelstad, M., Hass, U., Svingen, T., 2019. Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders. *Arch. Toxicol.* 93, 253-272. <https://doi.org/10.1007/s00204-018-2350-5>
- Supakar, P.C., Song, C.S., Jung, M.H., Slomczynska, M.A., Kim, J.M., Vellanoweth, R.L., Chatterjee, B., Roy, A.K., 1993. A novel regulatory element associated with age-dependent expression of the rat androgen receptor gene. *J. Biol. Chem.* 268, 26400-26408. [https://doi.org/10.1016/S0021-9258\(19\)74328-2](https://doi.org/10.1016/S0021-9258(19)74328-2)
- Tut, T.G., Ghadessy, F.J., Trifiro, M.A., Pinsky, L., Yong, E.L., 1997. Long Polyglutamine Tracts in the Androgen Receptor Are Associated with Reduced Trans-Activation, Impaired Sperm Production, and Male Infertility. *J. Clin. Endocrinol. Metab.* 82, 3777-3782. <https://doi.org/10.1210/jcem.82.11.4385>
- Williams, A.J., Grulke, C.M., Edwards, J., McEachran, A.D., Mansouri, K., Baker, N.C., Patlewicz, G., Shah, I., Wambaugh, J.F., Judson, R.S., Richard, A.M., 2017. The CompTox Chemistry Dashboard: a community data resource for environmental chemistry. *J. Cheminform.* 9, 61. <https://doi.org/10.1186/s13321-017-0247-6>
- Wu, D., Lin, G., Gore, A.C., 2009. Age-related Changes in Hypothalamic Androgen Receptor and Estrogen Receptor α in Male Rats. *J. Comp. Neurol.* 512, 688. <https://doi.org/10.1002/cne.21925>

Relationship: 2124: Decrease, AR activation leads to Altered, Transcription of genes by the AR

AOPs Referencing Relationship

AOP Name	Adjacency	Weight of Evidence	Quantitative Understanding
Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring	adjacent	High	
Androgen receptor (AR) antagonism leading to decreased fertility in females	adjacent	High	Moderate
5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring	adjacent	High	
Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring	adjacent	Moderate	

AOP Name	Adjacency	Weight of Evidence	Quantitative Understanding
Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring	adjacent	Moderate	Low
Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring	adjacent	High	
5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	adjacent	High	
5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring	adjacent	High	
Decreased testosterone synthesis leading to increased nipple retention (NR) in male (rodent) offspring	adjacent	High	
Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring	adjacent	High	

Evidence Supporting Applicability of this Relationship

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
mammals	mammals	High	NCBI

Life Stage Applicability

Life Stage	Evidence
During development and at adulthood	High

Sex Applicability

Sex	Evidence
Mixed	High

This KER is applicable for both sexes, across developmental stages into adulthood, in numerous cells and tissues and across mammalian taxa. It is, however, acknowledged that this KER most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Relationship Description

The androgen receptor (AR) is a ligand-dependent nuclear transcription factor that upon activation translocates to the nucleus, dimerizes, and binds androgen response elements (AREs) to modulate transcription of target genes (Lamont and Tindall, 2010, Roy et al. 2001). Decreased activation of the AR affects its transcription factor activity, therefore leading to altered AR-target gene expression. This KER refers to decreased AR activation and altered gene expression occurring in complex systems, such as *in vivo* and the specific effect on transcription of AR target genes will depend on species, life stage, tissue, cell type etc.

Evidence Supporting this KER

Biological Plausibility

The biological plausibility for this KER is considered high

The AR is a ligand-activated transcription factor part of the steroid hormone nuclear receptor family. Non-activated AR is found in the cytoplasm as a multiprotein complex with heat-shock proteins, immunophilins and, other chaperones (Roy et al. 2001). Upon activation through ligand binding, the AR dissociates from the protein complex, translocates to the nucleus and homodimerizes. Facilitated by co-regulators, AR can bind to DNA regions containing AREs and initiate transcription of target genes, that thus will be different in e.g. different tissues, life-stages, species etc.

Through mapping of AREs and ChIP sequencing studies, several AR target genes have been identified, mainly studied in prostate cells (Jin, Kim, and Yu 2013). Different co-regulators and ligands lead to altered expression of different sets of genes (Jin et al. 2013; Kanno et al. 2022). Alternative splicing of the AR can lead to different AR variants that also affects which genes are transcribed (Jin et al. 2013).

Apart from this canonical signaling pathway, the AR can suppress gene expression, indirectly regulate miRNA transcription, and have non-genomic effects by rapid activation of second messenger pathways in either presence or absence of a ligand (Jin et al. 2013).

Empirical Evidence

The empirical evidence for this KER is considered high

In humans, altered gene expression profiling in individuals with androgen insensitivity syndrome (AIS) can provide supporting empirical evidence (Holterhus et al. 2003; Peng et al. 2021). In rodent AR knockout (KO) models, gene expression profiling studies and gene-targeted approaches have provided information on differentially expressed genes in several organ systems including male and female reproductive, endocrine, muscular, cardiovascular and nervous systems (Denolet et al. 2006; Fan et al. 2005; Holterhus et al. 2003; Ikeda et al. 2005; Karlsson et al. 2016; MacLean et al. 2008; Rana et al. 2011; Russell et al. 2012; Shiina et al. 2006; Wang et al. 2006; Welsh et al. 2012; Willems et al. 2010; Yu et al. 2008, 2012; Zhang et al. 2006; Zhou et al. 2011).

Exposure to known antiandrogens has been shown to alter transcriptional profiles, for example of neonatal pig ovaries (Knapczyk-Stwora et al. 2019).

Dose concordance has also been observed for instance in zebrafish embryos; a dose of 50 µg/L of the AR antagonist flutamide resulted in 674 differentially expressed genes at 96 h post fertilization whereas 500 µg/L flutamide resulted in 2871 differentially expressed genes (Ayobahan et al., 2023).

Uncertainties and Inconsistencies

AR action has been reported to occur also without ligand binding. However, not much is known about the extent and biological implications of such non-canonical, ligand-independent AR activation (Bennesch and Picard 2015).

It should be noted that the AR-mediated transcription operates within a broader developmental context, where timing, temporal adaptation, tissue specificity, and local signaling environments, such as cofactor presence and receptor mutations, jointly determine transcriptional outcomes. While such contextual influences are acknowledged, the KER remains focused on effects of decreased AR activation on AR-mediated gene expression.

Quantitative Understanding of the Linkage

Response-response relationship

There is not enough data to define a quantitative relationship between AR activation and alteration of AR target gene transcription, and such a relationship will differ between biological systems (species, tissue, cell type, life stage etc).

Time-scale

AR and promoter interactions occur within 15 minutes of ligand binding, RNA polymerase II and coactivator recruitment are proposed to occur transiently with cycles of approximately 90 minutes in LNCaP cells (Kang et al. 2002). RNA polymerase II elongation rates in mammalian cells have been shown to range between 1.3 and 4.3 kb/min (Maiuri et al. 2011). Therefore, depending on the cell type and the half-life of the AR target gene transcripts, changes are to be expected within hours.

Known modulating factors

Modulating Factor (MF)	MF Specification	Effect(s) on the KER	Reference(s)
Age	AR expression in aging male rats	Tissue-specific alterations in AR activity with aging	(Supakar et al. 1993; Wu, Lin, and Gore 2009)
Genotype	Number of CAG repeats in the first exon of AR	Decreased AR activation with increased number of CAGs	(Tut et al. 1997; Chamberlain et al. 1994)

Known Feedforward/Feedback loops influencing this KER

AR has been hypothesized to auto-regulate its mRNA and protein levels (Mora and Mahesh 1999).

References

- Ayobahan, S. U., Alvincz, J., Reinwald, H., Strompen, J., Salinas, G., Schäfers, C., et al. (2023). Comprehensive identification of gene expression fingerprints and biomarkers of sexual endocrine disruption in zebrafish embryo. *Ecotoxicol. Environ. Saf.* 250, 114514. doi:10.1016/j.ECOENV.2023.114514.
- Bennesch, Marcela A., and Didier Picard. 2015. "Minireview: Tipping the Balance: Ligand-Independent Activation of Steroid Receptors." *Molecular Endocrinology* 29(3):349–63.
- Chamberlain, Nancy L., Erika D. Driverand, and Roger L. Miesfeldi. 1994. *The Length and Location of CAG Trinucleotide Repeats in the Androgen Receptor N-Terminal Domain Affect Transactivation Function*. Vol. 22.
- Denolet, Evi, Karel De Gendt, Joke Allemeersch, Kristof Engelen, Kathleen Marchal, Paul Van Hummelen, Karen A. L. Tan, Richard M. Sharpe, Philippa T. K. Saunders, Johannes V. Swinnen, and Guido Verhoeven. 2006. "The Effect of a Sertoli Cell-Selective Knockout of the Androgen Receptor on Testicular Gene Expression in Prepubertal Mice." *Molecular Endocrinology* 20(2):321–34. doi: 10.1210/me.2005-0113.

- Fan, Wuqiang, Toshihiko Yanase, Masatoshi Nomura, Taijiro Okabe, Kiminobu Goto, Takashi Sato, Hirotaka Kawano, Shigeaki Kato, and Hajime Nawata. 2005. *Androgen Receptor Null Male Mice Develop Late-Onset Obesity Caused by Decreased Energy Expenditure and Lipolytic Activity but Show Normal Insulin Sensitivity With High Adiponectin Secretion*. Vol. 54.
- Holterhus, Paul-Martin, Olaf Hiort, Janos Demeter, Patrick O. Brown, and James D. Brooks. 2003. *Differential Gene-Expression Patterns in Genital Fibroblasts of Normal Males and 46,XY Females with Androgen Insensitivity Syndrome: Evidence for Early Programming Involving the Androgen Receptor*. Vol. 4.
- Ikeda, Yasumasa, Ken Ichi Aihara, Takashi Sato, Masashi Akaike, Masanori Yoshizumi, Yuki Suzaki, Yuki Izawa, Mitsunori Fujimura, Shunji Hashizume, Midori Kato, Shusuke Yagi, Toshiaki Tamaki, Hirotaka Kawano, Takahiro Matsumoto, Hiroyuki Azuma, Shigeaki Kato, and Toshio Matsumoto. 2005. "Androgen Receptor Gene Knockout Male Mice Exhibit Impaired Cardiac Growth and Exacerbation of Angiotensin II-Induced Cardiac Fibrosis." *Journal of Biological Chemistry* 280(33):29661–66. doi: 10.1074/jbc.M411694200.
- Jin, Hong Jian, Jung Kim, and Jindan Yu. 2013. "Androgen Receptor Genomic Regulation." *Translational Andrology and Urology* 2(3):158–77.
- Kang, Zhigang, Asta Pirskanen, Olli A. Jänne, and Jorma J. Palvimo. 2002. "Involvement of Proteasome in the Dynamic Assembly of the Androgen Receptor Transcription Complex." *Journal of Biological Chemistry* 277(50):48366–71. doi: 10.1074/jbc.M209074200.
- Kanno, Yuichiro, Nao Saito, Ryota Saito, Tomohiro Kosuge, Ryota Shizu, Tomofumi Yatsu, Takuomi Hosaka, Kiyomitsu Nemoto, Keisuke Kato, and Kouichi Yoshinari. 2022. "Differential DNA-Binding and Cofactor Recruitment Are Possible Determinants of the Synthetic Steroid YK11-Dependent Gene Expression by Androgen Receptor in Breast Cancer MDA-MB 453 Cells." *Experimental Cell Research* 419(2). doi: 10.1016/j.yexcr.2022.113333.
- Karlsson, Sara A., Erik Studer, Petronella Kettunen, and Lars Westberg. 2016. "Neural Androgen Receptors Modulate Gene Expression and Social Recognition but Not Social Investigation." *Frontiers in Behavioral Neuroscience* 10(MAR). doi: 10.3389/fnbeh.2016.00041.
- Knapczyk-Stwora, Katarzyna, Anna Nynca, Renata E. Ciereszko, Lukasz Paukszt, Jan P. Jastrzebski, Elzbieta Czaja, Patrycja Witek, Marek Koziorowski, and Maria Slomczynska. 2019. "Flutamide-Induced Alterations in Transcriptional Profiling of Neonatal Porcine Ovaries." *Journal of Animal Science and Biotechnology* 10(1):1–15. doi: 10.1186/s40104-019-0340-y.
- Lamont, K. R., and Tindall, D. J. (2010). Androgen Regulation of Gene Expression. *Adv. Cancer Res.* 107, 137–162. doi:10.1016/S0065-230X(10)07005-3.
- MacLean, Helen E., W. S. Maria Chiu, Amanda J. Notini, Anna-Maree Axell, Rachel A. Davey, Julie F. McManus, Cathy Ma, David R. Plant, Gordon S. Lynch, and Jeffrey D. Zajac. 2008. "Impaired Skeletal Muscle Development and Function in Male, but Not Female, Genomic Androgen Receptor Knockout Mice ." *The FASEB Journal* 22(8):2676–89. doi: 10.1096/fj.08-105726.
- Maiuri, Paolo, Anna Knezevich, Alex De Marco, Davide Mazza, Anna Kula, Jim G. McNally, and Alessandro Marcello. 2011. "Fast Transcription Rates of RNA Polymerase II in Human Cells." *EMBO Reports* 12(12):1280–85. doi: 10.1038/embor.2011.196.
- Mora, Gloria R., and Virendra B. Mahesh. 1999. *Autoregulation of the Androgen Receptor at the Translational Level: Testosterone Induces Accumulation of Androgen Receptor MRNA in the Rat Ventral Prostate Polyribosomes*.
- Peng, Yajie, Hui Zhu, Bing Han, Yue Xu, Xuemeng Liu, Huaidong Song, and Jie Qiao. 2021. "Identification of Potential Genes in Pathogenesis and Diagnostic Value Analysis of Partial Androgen Insensitivity Syndrome Using Bioinformatics Analysis." *Frontiers in Endocrinology* 12. doi: 10.3389/fendo.2021.731107.
- Rana, Kesha, Barbara C. Fam, Michele V Clarke, Tammy P. S. Pang, Jeffrey D. Zajac, and Helen E. Maclean. 2011. "Increased Adiposity in DNA Binding-Dependent Androgen Receptor Knockout Male Mice Associated with Decreased Voluntary Activity and Not Insulin Resistance." *Am J Physiol Endocrinol Me-Tab* 301:767–78. doi: 10.1152/ajpendo.00584.2010.-In.
- Roy, Arun K., Rakesh K. Tyagi, Chung S. Song, Yan Lavrovsky, Soon C. Ahn, Tae Sung Oh, and Bandana Chatterjee. 2001. "Androgen Receptor: Structural Domains and Functional Dynamics after Ligand-Receptor Interaction." Pp. 44–57 in *Annals of the New York Academy of Sciences* Vol. 949. New York Academy of Sciences.
- Russell, Patricia K., Michele V. Clarke, Jarrod P. Skinner, Tammy P. S. Pang, Jeffrey D. Zajac, and Rachel A. Davey. 2012. "Identification of Gene Pathways Altered by Deletion of the Androgen Receptor Specifically in Mineralizing Osteoblasts and Osteocytes in Mice." *Journal of Molecular Endocrinology* 49(1):1–10. doi: 10.1530/JME-12-0014.
- Shiina, Hiroko, Takahiro Matsumoto, Takashi Sato, Katsuhide Igarashi, Junko Miyamoto, Sayuri Takemasa, Matomo Sakari, Ichiro Takada, Takashi Nakamura, Daniel Metzger, Pierre Chambon, Jun Kanno, Hiroyuki Yoshikawa, and Shigeaki Kato. 2006. *Premature Ovarian Failure in Androgen Receptor-Deficient Mice* Vol. 103.
- Supakar, P. C., C. S. Song, M. H. Jung, M. A. Slomczynska, J. M. Kim, R. L. Vellanoweth, B. Chatterjee, and A. K. Roy. 1993. "A Novel Regulatory Element Associated with Age-Dependent Expression of the Rat Androgen Receptor Gene." *Journal of Biological Chemistry* 268(35):26400–408. doi: 10.1016/s0021-9258(19)74328-2.

- Tut, Thein G., Farid J. Ghadessy, M. A. Trifiro, L. Pinsky, and E. L. Yong. 1997 *Long Polyglutamine Tracts in the Androgen Receptor Are Associated with Reduced Trans-Activation, Impaired Sperm Production, and Male Infertility**. Vol. 82.
- Wang, Ruey Sheng, Shuyuan Yeh, Lu Min Chen, Hung Yun Lin, Caixia Zhang, Jing Ni, Cheng Chia Wu, P. Anthony Di Sant'Agnese, Karen L. DeMesy-Bentley, Chii Ruey Tzeng, and Chawnshang Chang. 2006. "Androgen Receptor in Sertoli Cell Is Essential for Germ Cell Nursery and Junctional Complex Formation in Mouse Testes." *Endocrinology* 147(12):5624-33. doi: 10.1210/en.2006-0138.
- Welsh, M., L. Moffat, K. Belling, L. R. de França, T. M. Segatelli, P. T. K. Saunders, R. M. Sharpe, and L. B. Smith. 2012. "Androgen Receptor Signalling in Peritubular Myoid Cells Is Essential for Normal Differentiation and Function of Adult Leydig Cells." *International Journal of Andrology* 35(1):25-40. doi: 10.1111/j.1365-2605.2011.01150.x.
- Willems, Ariane, Sergio R. Batlouni, Arantza Esnal, Johannes V. Swinnen, Philippa T. K. Saunders, Richard M. Sharpe, Luiz R. França, Karel de Gendt, and Guido Verhoeven. 2010. "Selective Ablation of the Androgen Receptor in Mouse Sertoli Cells Affects Sertoli Cell Maturation, Barrier Formation and Cytoskeletal Development." *PLoS ONE* 5(11). doi: 10.1371/journal.pone.0014168.
- Wu, D. I., Grace Lin, and Andrea C. Gore. 2009. "Age-Related Changes in Hypothalamic Androgen Receptor and Estrogen Receptor in Male Rats." *The Journal of Comparative Neurology* 512:688-701. doi: 10.1002/cne.21925.
- Yu, I. Chen, Hung Yun Lin, Ning Chun Liu, Ruey Shen Wang, Janet D. Sparks, Shuyuan Yeh, and Chawnshang Chang. 2008. "Hyperleptinemia without Obesity in Male Mice Lacking Androgen Receptor in Adipose Tissue." *Endocrinology* 149(5):2361-68. doi: 10.1210/en.2007-0516.
- Yu, Shengqiang, Chiu Ren Yeh, Yuanjie Niu, Hong Chiang Chang, Yu Chieh Tsai, Harold L. Moses, Chih Rong Shyr, Chawnshang Chang, and Shuyuan Yeh. 2012. "Altered Prostate Epithelial Development in Mice Lacking the Androgen Receptor in Stromal Fibroblasts." *Prostate* 72(4):437-49. doi: 10.1002/pros.21445.
- Zhang, Caixia, Shuyuan Yeh, Yen-Ta Chen, Cheng-Chia Wu, Kuang-Hsiang Chuang, Hung-Yun Lin, Ruey-Sheng Wang, Yu-Jia Chang, Chamindrani Mendis-Handagama, Liquan Hu, Henry Lardy, Chawnshang Chang, and † † George. 2006. *Oligozoospermia with Normal Fertility in Male Mice Lacking the Androgen Receptor in Testis Peritubular Myoid Cells*
- Zhou, Wei, Gensheng Wang, Christopher L. Small, Zhilin Liu, Connie C. Weng, Lizhong Yang, Michael D. Griswold, and Marvin L. Meistrich. 2011. "Erratum: Gene Expression Alterations by Conditional Knockout of Androgen Receptor in Adult Sertoli Cells of Utp14bjsd/Jsd (Jsd) Mice (Biology of Reproduction (2010) 83, (759-766) DOI: 10.1095/Biolreprod.110.085472)." *Biology of Reproduction* 84(2):400-408.

List of Non Adjacent Key Event Relationships

Relationship: 2828: Decrease, AR activation leads to Hypospadias

AOPs Referencing Relationship

AOP Name	Adjacency	Weight of Evidence	Quantitative Understanding
Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring	non-adjacent	High	
Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring	non-adjacent	High	
5α-reductase inhibition leading to hypospadias in male (mammalian) offspring	non-adjacent	High	

Evidence Supporting Applicability of this Relationship

Taxonomic Applicability

Term	Scientific Term	Evidence	Links
human	Homo sapiens	High	NCBI
rat	Rattus norvegicus	High	NCBI
mouse	Mus musculus	Moderate	NCBI

Life Stage Applicability

Life Stage Evidence

Foetal High

Sex Applicability

Sex Evidence

Male High

Taxonomic applicability

In mammals, androgens are one of the primary drivers of penis differentiation. Hypospadias has been observed in several mammals, but most frequently reported in laboratory rodents and in humans (Chang et al., 2020; S. Wang & Zheng, 2025). *In vivo* studies in rats and mice show that *in utero* exposure to anti-androgenic chemicals can cause hypospadias in male offspring (see Table 3). Many human case studies report boys born with hypospadias and associated deficiency in steroid hormone synthesis, 5 α -reductase activity, or AR activity (see table 4).

The biologically plausible domain of applicability may extend beyond the empirical domain because androgen-controlled development of male external genitalia is evolutionary conserved in most mammals and, to some extent, also in other vertebrate classes (Gredler et al., 2014). Hypospadias can in principle occur in all animals that form a genital tubercle and have been observed in many domestic animal species including dog (Sonne et al., 2008; Switonski et al., 2018), cat (Nowacka-Woszek et al., 2014), cattle (Murakami, 2008), sheep (Smith et al., 2012), and horse (De Lorenzi et al., 2010) as well as in wildlife species such as polar bear (Stamper et al., 1999), giraffe (Meuffels et al., 2020), and Tamar Wallaby (Leihy et al., 2011). The observed hypospadias in these animals is not, *per se*, linked to anti-androgenic exposure, which has only been sparsely investigated in other species than mice, rats, and humans. One study in monkeys did show hypospadias upon oral exposure to finasteride (Pralhada et al., 1997), and bicalutamide exposure induced hypospadias in guinea pigs (S. Wang et al., 2018). A study in rabbits exposed to procymidone did not find hypospadias in males (Inawaka et al., 2010). Another study in hyenas did also not find hypospadias in males after exposure to the anti-androgen finasteride (Drea et al., 1998), but it should be noted that the hyenas have a remarkable sexual development where penile growth occur in both females and males before androgen synthesis is initiated (Cunha et al., 2014) (the studies in hyena and rabbit were identified in our evidence collection but were judged as 'unreliable' and therefore not included as empirical evidence).

Sex applicability

The AR is expressed in the fetal genital tubercle of both females and males (Amato & Yao, 2021; Baskin et al., 2020), but hypospadias is primarily a term used for a malformation of the penis (Baskin & Ebbers, 2006), limiting the applicability of this KER to males.

Life stage applicability

Differentiation of the penis occurs during fetal life in the masculinization programming window (GD 16-20 in rats, around GW 8-14 in humans), when androgen production is high (Welsh et al., 2008; C. Wolf et al., 2000a). In rats, exposure to anti-androgenic chemicals outside of, or in the late part of the masculinization programming window does not cause hypospadias or only to a low degree (Clark et al., 1993; van den Driesche et al., 2017; C. Wolf et al., 2000a), while exposure in the earlier (or full) window causes a higher frequency of hypospadias (depending on dose and chemical) (Table 3). In humans, hypospadias can be diagnosed at birth (X. Yu et al., 2019), while in rodents, some parts of penis development occur postnatally (Schlomer et al., 2013; Sinclair et al., 2017). In these species, hypospadias may be observed at birth but is optimally diagnosed and severity classified weeks later. Given that disruptions to androgen programming takes place in fetal life, even though the AO is best detected postnatally, the life stage applicability is defined as fetal life.

Key Event Relationship Description

This non-adjacent KER describes a fetal decrease in androgen receptor (AR) activation in the genital tubercle causing hypospadias in male offspring, postnatally. During fetal development, androgens induce differentiation of the bipotential genital tubercle to a penis, including closure of the urethra. Androgens signal through AR and reduced fetal AR activation can therefore disrupt penis differentiation and lead to the genital malformation hypospadias. Reduced AR activation may happen both through reduced ligand availability (testosterone or dihydrotestosterone (DHT)) and by direct antagonism of AR (Amato et al., 2022; Mattiske & Pask, 2021).

The upstream KE 'decrease, androgen receptor activation' (KE 1614) refers to the *in vivo* event of overall reduction in AR activation. In this case, it therefore refers to a reduction in AR activation in the genital tubercle. Currently, decreased AR activation in mammals is only directly measured *in vitro* and not *in vivo*. Instead, indirect assessment of this KE may come from assays measuring AR antagonism, 5 α -reductase activity (the enzyme converting testosterone to DHT), or decreased androgen levels (Draskau et al., 2024).

Evidence Supporting this KER

Biological Plausibility

The biological plausibility for this KER is judged as **high**. This is largely based on canonical knowledge on normal reproductive development.

The penis originates from a sexually bipotential structure, the genital tubercle, which may differentiate to either a penis or a clitoris, depending on internal cues during fetal development. In males, the fetal testes produce large amounts of testosterone, which can subsequently be converted to the more potent androgen DHT by 5 α -reductase in peripheral tissues. Testosterone and DHT both signal through AR in target tissues to initiate masculinization (Amato et al., 2022; Murashima et al., 2015). The critical developmental window for androgen programming of masculinization has been identified in rats as gestational days

(GD) 16-20, and is proposed to be gestational weeks 8-14 in humans (Sharpe, 2020; Welsh et al., 2008). As part of the masculinization process orchestrated by androgens, the genital tubercle, which at this point expresses AR in both humans and rodents, differentiates to a penis (Amato & Yao, 2021; Baskin et al., 2020). This includes androgen-mediated elongation of the tubercle, formation of the prepuce, and tubular internalization of urethra, which is closed at the distal tip of the glans penis (Amato et al., 2022). Failure of full closure of the urethra can result in hypospadias, in which the urethra terminates at the ventral side of the penis instead of at the tip (Baskin & Ebberts, 2006; Cohn, 2011).

The dependency of androgens for penile development has been demonstrated in mice with conditional or full knockout of *Ar*, which results in partly or full sex-reversal of males, including a female-like urethral opening (Willingham et al., 2006; Yucel et al., 2004; Zheng et al., 2015). Similarly, female rats and mice exposed *in utero* to testosterone present with varying degrees of intersexuality, including, in some cases, a penis (Greene & Ivy, 1937; Zheng et al., 2015).

Empirical Evidence

The empirical evidence for this KER is generally judged as **high**. This includes evidence from *in vivo* animal studies and supporting evidence from studies in humans. The upstream KE 'Decreased AR activation' refers to an *in vivo* effect, for which no methods for measurement of this *in vivo* in mammals currently exist. The effects on the upstream KE were therefore indirectly informed as described in each section.

Animal studies

Effects on the upstream KE were indirectly informed by including animal studies with stressors that are known to reduce AR activity by antagonizing the AR, lowering testosterone production, or inhibiting 5 α -reductase. Six stressors, with established anti-androgenic effects, were included (more detailed evaluation of these chemicals can be found in KER-2820 (Holmer et al., 2024)). Table 3 summarizes the empirical evidence and confidence level for each chemical. Details on included evidence is presented in Table 1 in Appendix 2, [9prbqyba2x_Appendix_2_KER_2828.pdf](#). In summary, all six substances were shown to cause hypospadias in male offspring, and the confidence level for all substances was judged as strong, as conflicting results could be explained (see the section 'Uncertainties and inconsistencies'). Thus, antagonism of AR, inhibition of 5 α -reductase, or reduction in testosterone synthesis, all lead to hypospadias.

Table 3 Summary of empirical evidence for the KER - animal studies . See Table 1 in Appendix 2 ([9prbqyba2x_Appendix_2_KER_2828.pdf](#)) for details.

Chemical	Upstream effect	Downstream effect	Overall confidence
Flutamide	Androgen receptor antagonist (Simard et al., 1986).	<i>In utero</i> exposure causes hypospadias in rat and mouse	Strong
Dibutyl phthalate (DBP)	Has been shown to reduce fetal intratesticular testosterone and serum testosterone <i>in vivo</i> , but exact mechanism is unknown (Foster, 2006).	<i>In utero</i> exposure causes hypospadias in rat	Strong
Vinclozolin	AR antagonist (Kelce et al., 1994, 1997)	<i>In utero</i> exposure causes hypospadias in rat and mouse	Strong
Di(2-ethylhexyl) phthalate (DEHP)	Has been shown to reduce fetal intratesticular testosterone and serum testosterone <i>in vivo</i> , but exact mechanism is unknown (Parks et al., 2000).	<i>In utero</i> exposure causes hypospadias in rat	Strong
Procymidone	AR antagonist (Ostby et al., 1999).	<i>In utero</i> exposure causes hypospadias in rat	Strong
Finasteride	5 α -reductase inhibitor, causing a reduction in DHT (Rittmaster & Wood, 1994).	<i>In utero</i> exposure causes hypospadias in rat	Strong

Supporting human evidence

Effects on the upstream KE were indirectly informed by including studies in humans with a condition (genetic or other) that would reduce or disrupt either 1) function of AR, 2) conversion of testosterone to DHT by disrupting 5 α -reductase activity, or 3) production of androgen hormones. Studies measuring low testosterone levels with no underlying cause were also included (see evidence collection strategy). Table 4 lists the studies, in which these conditions were linked to hypospadias in males.

Table 4 Supporting evidence for the KER - human studies. The table lists the number of human studies reporting hypospadias in association with an upstream defect in AR activity, grouped according to the precise effect, and how it was diagnosed (mutation, *in vitro* activity, or blood hormone and metabolite profile). SRD5A2: 5 α -reductase 2; HSD17B3: 17 β -hydroxysteroid dehydrogenase 3; HSD3B2: 3 β -hydroxysteroid dehydrogenase 2; CYP17A1: 17 α -hydroxylase. See Table 2 in

Appendix 2 ([9prbqyba2x_Appendix_2_KER_2828.pdf](#)) for all included references.

Effect on upstream KE	Supporting studies
<i>Effects on Androgen receptor</i>	
AR mutations	27 studies
Extended CAG repeat length in AR	4 studies
Reduced AR activity (e.g. low receptor binding) in <i>in vitro</i> genital skin fibroblasts	11 studies
<i>Effects on 5α-reductase activity</i>	
SRD5A2 mutations	30 studies
SRD5A2 deficiency, diagnosed by T/DHT-ratio and/or reduced <i>in vitro</i> 5α-reductase activity in genital skin fibroblasts	8 studies
<i>Effects on upstream steroidogenesis enzymes</i>	
HSD17B3 mutations	6 studies
HSD3B2 mutations	5 studies
CYP17A1 mutation	1 study
HSD17B3 deficiency, diagnosed by hormone and metabolite profile	2 studies
HSD3B2 deficiency, diagnosed by hormone and metabolite profile	4 studies
CYP17A1 deficiency, diagnosed by hormone and metabolite profile	5 studies
<i>Other upstream effects on low testosterone</i>	
Low testosterone due to gonadal dysgenesis or hypogonadism	7 studies
Low basal testosterone or low testosterone response to hCG stimulation. Idiopathic or rare mutations.	7 studies

Six case-control studies were extracted, all of which found a correlation between lower testosterone levels (basal or hCG-stimulated) and hypospadias (Austin et al., 2002; Okuyama et al., 1981; Raboch et al., 1976; Ratan et al., 2012; Svensson et al., 1979; Yadav et al., 2011). In two of these studies, the correlation was age-dependent (Austin et al., 2002; Raboch et al., 1976)

One epidemiologic study was extracted, which investigated the association between phthalate exposure and hypospadias risk. Western Australian women exposed through their occupation to phthalates were more likely to have sons with hypospadias (Nassar et al., 2010). It should be noted that there are reported species differences in the effects of phthalates (including DEHP and DBP) on fetal testosterone production between humans, mice, and rats, and the direct translatability of the *in vivo* evidence is uncertain (Sharpe, 2020).

Dose concordance

Information about dose concordance is not available because AR activity currently cannot be measured *in vivo*.

Temporal concordance

Direct information about temporal concordance is not available because AR activity currently cannot be measured *in vivo*.

Indirect information on temporal concordance can be obtained from empirical evidence. In two studies, in which rats were exposed *in utero* to 750 mg/kg bw/day DBP, intratesticular testosterone levels were reduced in fetal testes, while hypospadias was identified in adult males. Plasma levels of testosterone were also measured in adults, and testosterone levels in exposed males were not significantly different from control males (van den Driesche et al., 2017, 2020). This has also been shown in a study with 500 mg/kg bw/day DBP (Drake et al., 2009). These studies indicate temporal concordance.

Incidence Concordance

Information about dose concordance is not available because AR activity currently cannot be measured *in vivo*.

Uncertainties and Inconsistencies

The *in vivo* studies do not directly inform about the upstream KE, 'decrease, AR activation'. The direct concordance between the KEs can therefore not be determined from the evidence.

For flutamide, two studies reported 100% hypospadias frequencies at doses of 6.25 and 10 mg/kg bw/day (Goto et al., 2004; McIntyre et al., 2001), while another study found a frequency of 56.9% when giving 20 mg/kg bw/day (Kita et al., 2016). This might be explained by a longer exposure window in the first two studies and uncertainties in assessment of hypospadias.

For DBP, there were discrepancies in whether 250 mg/kg bw/day was LOAEL (Mylchreest et al., 1998, 1999) or NOAEL (Jiang et al., 2007) for DBP. This conflict was explained by differences in exposure windows, supported by the observation that the frequency of hypospadias at 250 mg/kg bw/day was reported as very low (Mylchreest et al., 1998, 1999).

One study with vinclozolin (Ostby J et al., 1999) and one with procymidone (Hass et al., 2012) did not find hypospadias after *in utero* exposure. In both cases, this was likely due to too low doses tested.

In most of the human studies of steroidogenesis deficiency, serum or plasma levels of testosterone were reduced at baseline and/or upon hCG stimulation (Al-Sinani et al., 2015; Ammini et al., 1997; Cara et al., 1985; Chen, Huang, et al., 2021; Dean et al., 1984; Galli-Tsinopoulou et al., 2018; Imperato-McGinley et al., 1979; Kaufman et al., 1983; Mendonca et al., 1987, 2000; Neocleous et al., 2012; New, 1970; Pang et al., 1983; Perrone et al., 1985; Rabbani et al., 2012; Sherbet et al., 2003), but in a few studies, testosterone levels were normal (Donadille et al., 2018; Kon et al., 2015; Luna et al., 2021). In these cases, the

effect of these deficiencies on tissue AR activation is uncertain.

For *AR* CAG repeat length, a case-control study did not find an association with hypospadias (Radpour R et al., 2007), but this could be because the hypospadias cases included had other etiologies.

Lastly, as there are currently no universal guidelines for identification and scoring of hypospadias in rodents, there are large variations in methods of assessment, and minor cases of hypospadias may be overlooked in some studies and included in others. This poses an uncertainty in the frequency reports in the scientific evidence.

Quantitative Understanding of the Linkage

The quantitative understanding of the relationship is low. As there are currently no direct measurement methods of the upstream KE (reduced AR activation) in mammals, quantification of the relationship is difficult to assess.

Response-response relationship

A model for phthalates has been developed, aiming to predict the frequency of hypospadias in male offspring based on reductions in *ex vivo* testosterone production, an indirect indication of AR activation. In this model, hypospadias was induced from around a 60% reduction in testosterone levels. The model does not consider hypospadias severity and is only for phthalate chemicals (Earl Gray et al., 2024).

Time-scale

The time-scale of this KER depends on the species but is likely days to weeks.

AR activation happens within minutes, from ligand binding to nuclear translocation and promotor activation (Nightingale et al., 2003; Schaufele et al., 2005), while transcriptional and translational effects are observed minutes to hours later (Kang et al., 2002). AR programming of the genital tubercle occurs during fetal development in the masculinization programming window (Sharpe, 2020). The time-scale for morphological effects in the tissue then depends on the species. In humans, penis development is completed prior to birth and hypospadias can be observed at birth. In rodents, penis development is not fully completed until weeks after birth, but hypospadias can often be observed earlier than this (Table 3).

Known modulating factors

Modulating Factors	MF details	Effects on the KER	References
<i>AR</i> CAG repeat length	Extended CAG repeat length in <i>AR</i> is associated with reduced AR activity	Higher risk of hypospadias development	(Chamberlain et al., 1994)

Known Feedforward/Feedback loops influencing this KER

Local disruption of AR activation in the genital tubercle irreversibly disrupts development, so there are no known feedforward/feedback loops.

References

- Al-Sinani, A., Mula-Abed, W., Al-Kindi, M., Al-Kusaibi, G., Al-Azkawi, H., & Nahavandi, N. (2015). A Novel Mutation Causing 17- β -Hydroxysteroid Dehydrogenase Type 3 Deficiency in an Omani Child: First Case Report and Review of Literature. *Oman Medical Journal*, 30(2), 129–134. <https://doi.org/10.5001/omj.2015.27>
- Amato, C. M., & Yao, H. H.-C. (2021). Developmental and sexual dimorphic atlas of the prenatal mouse external genitalia at the single-cell level. *Proceedings of the National Academy of Sciences of the United States of America*, 118(25). <https://doi.org/10.1073/pnas.2103856118>
- Amato, C. M., Yao, H. H.-C., & Zhao, F. (2022). One Tool for Many Jobs: Divergent and Conserved Actions of Androgen Signaling in Male Internal Reproductive Tract and External Genitalia. *Frontiers in Endocrinology*, 13, 910964. <https://doi.org/10.3389/fendo.2022.910964>
- Ammini, A., Sharma, D., Gupta, R., Mohapatra, I., Kucheria, K., Kriplani, A., Takkar, D., Mitra, D., & Vijayaraghavan, M. (1997). Familial male pseudohermaphroditism. *Indian Journal of Pediatrics*, 64(3), 419–423. <https://doi.org/10.1007/BF02845218>
- Austin, P., Siow, Y., Fallat, M., Cain, M., Rink, R., & Casale, A. (2002). The relationship between müllerian inhibiting substance and androgens in boys with hypospadias. *The Journal of Urology*, 168(4), 1784–1788; discussion 1788. <https://doi.org/10.1097/01.ju.0000023680.64155.5c>
- Baskin, L., Cao, M., Sinclair, A., Li, Y., Overland, M., Isaacson, D., & Cunha, G. R. (2020). Androgen and estrogen receptor expression in the developing human penis and clitoris. *Differentiation; Research in Biological Diversity*, 111, 41–59. <https://doi.org/10.1016/j.diff.2019.08.005>
- Baskin, L., & Ebbers, M. (2006). Hypospadias: Anatomy, etiology, and technique. *Journal of Pediatric Surgery*, 41(3), 463–472. <https://doi.org/10.1016/j.jpedsurg.2005.11.059>
- Cara, J., Jr Moshang, T., Bongiovanni, A., & Marx, B. (1985). Elevated 17-hydroxyprogesterone and testosterone in a newborn

with 3-beta-hydroxysteroid dehydrogenase deficiency. *The New England Journal of Medicine*, 313(10), 618–621. <https://doi.org/10.1056/NEJM198509053131007>

Chamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994). The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Research*, 22(15), 3181–3186. <https://doi.org/10.1093/nar/22.15.3181>

Chang, J., Wang, S., & Zheng, Z. (2020). Etiology of Hypospadias: A Comparative Review of Genetic Factors and Developmental Processes Between Human and Animal Models. *Research and Reports in Urology, Volume 12*, 673–686. <https://doi.org/10.2147/RRU.S276141>

Chen, L., Huang, H., Zhang, H., Zhu, G., & Zhu, M. (2021). Three cases of 3 β -hydroxysteroid dehydrogenase deficiency: Clinical analysis. *Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University*, 30(3), 289–299. <https://doi.org/10.17219/acem/131220>

Clark, R., Anderson, C., Prahalada, S., Robertson, R., Lochry, E., Leonard, Y., Stevens, J., & Hoberman, A. (1993). Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5 alpha-reductase inhibitor. *Toxicology and Applied Pharmacology*, 119(1), 34–40. <https://doi.org/10.1006/taap.1993.1041>

Cohn, M. J. (2011). Development of the external genitalia: Conserved and divergent mechanisms of appendage patterning. *Developmental Dynamics*, 240(5), 1108–1115. <https://doi.org/10.1002/dvdy.22631>

Cunha, G. R., Risbridger, G., Wang, H., Place, N. J., Grumbach, M., Cunha, T. J., Weldele, M., Conley, A. J., Barcellos, D., Agarwal, S., Bhargava, A., Drea, C., Hammond, G. L., Siiteri, P., Coscia, E. M., McPhaul, M. J., Baskin, L. S., & Glickman, S. E. (2014). Development of the external genitalia: Perspectives from the spotted hyena (*Crocuta crocuta*). *Differentiation*, 87(1–2), 4–22. <https://doi.org/10.1016/j.diff.2013.12.003>

De Lorenzi, L., Genuardo, V., Iannuzzi, A., Di Meo, G. P., Perucatti, A., Mancuso, R., Russo, M., Di Berardino, D., Parma, P., & Iannuzzi, L. (2010). Cytogenetic and Genetic Studies in a Hypospadiac Horse (*Equus caballus*, 2n = 64). *Sexual Development*, 4(6), 352–357. <https://doi.org/10.1159/000319527>

Dean, H., Shackleton, C., & Winter, J. (1984). Diagnosis and natural history of 17-hydroxylase deficiency in a newborn male. *The Journal of Clinical Endocrinology and Metabolism*, 59(3), 513–520. <https://doi.org/10.1210/jcem-59-3-513>

Donadille, B., Houang, M., Netchine, I., Siffroi, J., & Christin-Maitre, S. (2018). Human 3beta-hydroxysteroid dehydrogenase deficiency associated with normal spermatid numeration despite a severe enzyme deficit. *Endocrine Connections*, 7(3), 395–402. <https://doi.org/10.1530/EC-17-0306>

Drake, A., van den Driesche, S., Scott, H., Hutchison, G., Seckl, J., & Sharpe, R. (2009). Glucocorticoids amplify dibutyl phthalate-induced disruption of testosterone production and male reproductive development. *Endocrinology*, 150(11), 5055–5064. <https://doi.org/10.1210/en.2009-0700>

Draskau, M. K., Rosenmai, A. K., Bouftas, N., Johansson, H. K. L., Panagiotou, E. M., Holmer, M. L., Elmélund, E., Zilliacus, J., Beronius, A., Damdimopolou, P., van Duursen, M., & Svingen, T. (2024). AOP Report: An Upstream Network for Reduced Androgen Signaling Leading to Altered Gene Expression of Androgen Receptor-Responsive Genes in Target Tissues. *Environmental Toxicology and Chemistry*. <https://doi.org/10.1002/etc.5972>

Drea, C., Weldele, M., Forger, N., Coscia, E., Frank, L., Licht, P., & Glickman, S. (1998). Androgens and masculinization of genitalia in the spotted hyaena (*Crocuta crocuta*). 2. Effects of prenatal anti-androgens. *Journal of Reproduction and Fertility*, 113(1), 117–127. <https://doi.org/10.1530/jrf.0.1130117>

Earl Gray, L. J., Lambright, C., Evans, N., Ford, J., & Conley, M. (2024). Using targeted fetal rat testis genomic and endocrine alterations to predict the effects of a phthalate mixture on the male reproductive tract. *Current Research in Toxicology*, 7, 100180. <https://doi.org/10.1016/j.crttox.2024.100180>

Foster, P. M. D. (2006). Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. *International Journal of Andrology*, 29(1), 140–147. <https://doi.org/10.1111/j.1365-2605.2005.00563.x>

Galli-Tsinopoulou, A., Serbis, A., Kotanidou, E., Litou, E., Dokousli, V., Mouzaki, K., Fanis, P., Neocleous, V., & Skordis, N. (2018). 46,XY Disorder of Sex Development due to 17-Beta Hydroxysteroid Dehydrogenase Type 3 Deficiency in an Infant of Greek Origin. *Journal of Clinical Research in Pediatric Endocrinology*, 10(1), 74–78. <https://doi.org/10.4274/jcrpe.4829>

Goto, K., Koizumi, K., Takaori, H., Fujii, Y., Furuyama, Y., Saika, O., Suzuki, H., Saito, K., & Suzuki, K. (2004). Effects of flutamide on sex maturation and behavior of offspring born to female rats treated during late pregnancy. *The Journal of Toxicological Sciences*, 29(5), 517–534. <https://doi.org/10.2131/jts.29.517>

Gredler, M. L., Larkins, C. E., Leal, F., Lewis, A. K., Herrera, A. M., Perriton, C. L., Sanger, T. J., & Cohn, M. J. (2014). Evolution of External Genitalia: Insights from Reptilian Development. *Sexual Development*, 8(5), 311–326. <https://doi.org/10.1159/000365771>

Greene, R. R., & Ivy, A. C. (1937). THE EXPERIMENTAL PRODUCTION OF INTERSEXUALITY IN THE FEMALE RAT WITH TESTOSTERONE. *Science (New York, N.Y.)*, 86(2226), 200–201. <https://doi.org/10.1126/science.86.2226.200-a>

Hass, U., Boberg, J., Christiansen, S., Jacobsen, P., Vinggaard, A., Taxvig, C., Poulsen, M., Herrmann, S., Jensen, B., Petersen, A., Clemmensen, L., & Axelstad, M. (2012). Adverse effects on sexual development in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides. *Reproductive Toxicology (Elmsford, N.Y.)*, 34(2), 261–274.

<https://doi.org/10.1016/j.reprotox.2012.05.090>

Holmer, M. L., Zilliacus, J., Draskau, M. K., Hliseníková, H., Beronius, A., & Svingen, T. (2024). Methodology for developing data-rich Key Event Relationships for Adverse Outcome Pathways exemplified by linking decreased androgen receptor activity with decreased anogenital distance. *Reproductive Toxicology*, 128, 108662. <https://doi.org/10.1016/j.reprotox.2024.108662>

Imperato-McGinley, J., Peterson, R., Stoller, R., & Goodwin, W. (1979). Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: Gender role change with puberty. *The Journal of Clinical Endocrinology and Metabolism*, 49(3), 391–395. <https://doi.org/10.1210/jcem-49-3-391>

Inawaka, K., Kishimoto, N., Higuchi, H., & Kawamura, S. (2010). Maternal exposure to procymidone has no effects on fetal external genitalia development in male rabbit fetuses in a modified developmental toxicity study. *JOURNAL OF TOXICOLOGICAL SCIENCES*, 35(3), 299–307. <https://doi.org/10.2131/jts.35.299>

Jiang, J., Ma, L., Yuan, L., Wang, X., & Zhang, W. (2007). Study on developmental abnormalities in hypospadiac male rats induced by maternal exposure to di-n-butyl phthalate (DBP). *Toxicology*, 232(3), 286–293. <https://doi.org/10.1016/j.tox.2007.01.018>

Jiang, J., Zhong, C., Zhu, Y., Xu, D., Wood, K., Sun, W., Li, E., Liu, Z., Zhao, W., Ruan, Y., & Xia, S. (2016). Prenatal exposure to di-n-butyl phthalate (DBP) differentially alters androgen cascade in undeformed versus hypospadiac male rat offspring. *Reproductive Toxicology (Elmsford, N.Y.)*, 61, 75–81. <https://doi.org/10.1016/j.reprotox.2016.02.016>

Kang, H.-Y., Huang, K.-E., Chang, S. Y., Ma, W.-L., Lin, W.-J., & Chang, C. (2002). Differential Modulation of Androgen Receptor-mediated Transactivation by Smad3 and Tumor Suppressor Smad4. *Journal of Biological Chemistry*, 277(46), 43749–43756. <https://doi.org/10.1074/jbc.M205603200>

Kaufman, F., Costin, G., Goebelsmann, U., Stanczyk, F., & Zachmann, M. (1983). Male pseudohermaphroditism due to 17,20-desmolase deficiency. *The Journal of Clinical Endocrinology and Metabolism*, 57(1), 32–36. <https://doi.org/10.1210/jcem-57-1-32>

Kelce, W. R., Lambright, C. R., Gray, L. E., & Roberts, K. P. (1997). Vinclozolin andp,p'-DDE Alter Androgen-Dependent Gene Expression:In VivoConfirmation of an Androgen Receptor-Mediated Mechanism. *Toxicology and Applied Pharmacology*, 142(1), 192–200. <https://doi.org/10.1006/taap.1996.7966>

Kelce, W. R., Monosson, E., Gamcsik, M. P., Laws, S. C., & Gray, L. E. (1994). Environmental Hormone Disruptors: Evidence That Vinclozolin Developmental Toxicity Is Mediated by Antiandrogenic Metabolites. *Toxicology and Applied Pharmacology*, 126(2), 276–285. <https://doi.org/10.1006/taap.1994.1117>

Kita, D., Meyer, K., Venturelli, A., Adams, R., Machado, D., Morais, R., Swan, S., Gennings, C., & Martino-Andrade, A. (2016). Manipulation of pre and postnatal androgen environments and anogenital distance in rats. *TOXICOLOGY*, 368, 152–161. <https://doi.org/10.1016/j.tox.2016.08.021>

Kon, M., Suzuki, E., Dung, V., Hasegawa, Y., Mitsui, T., Muroyas, K., Ueoka, K., Igarashi, N., Nagasaki, K., Oto, Y., Hamajima, T., Yoshino, K., Igarashi, M., Kato-Fukui, Y., Nakabayashi, K., Hayashi, K., Hata, K., Matsubara, Y., Moriya, K., ... Fukami, M. (2015). Molecular basis of non-syndromic hypospadias: Systematic mutation screening and genome-wide copy-number analysis of 62 patients. *HUMAN REPRODUCTION*, 30(3), 499–506. <https://doi.org/10.1093/humrep/deu364>

Lei, M. W., Shaw, G., Wilson, J. D., & Renfree, M. B. (2011). Development of the Penile Urethra in the Tammar Wallaby. *Sexual Development*, 5(5), 241–249. <https://doi.org/10.1159/000334053>

Luna, S., Wegner, D., Gale, S., Yang, P., Hollander, A., St Dennis-Feezle, L., Nabhan, Z., Ory, D., Cole, F., & Wambach, J. (2021). Whole exome sequencing and functional characterization increase diagnostic yield in siblings with a 46, XY difference of sexual development (DSD). *The Journal of Steroid Biochemistry and Molecular Biology*, 212, 105908. <https://doi.org/10.1016/j.jsbmb.2021.105908>

Mattiske, D. M., & Pask, A. J. (2021). Endocrine disrupting chemicals in the pathogenesis of hypospadias; developmental and toxicological perspectives. *Current Research in Toxicology*, 2, 179–191. <https://doi.org/10.1016/j.crttox.2021.03.004>

McIntyre, B., Barlow, N., & Foster, P. (2001). Androgen-mediated development in male rat offspring exposed to flutamide in utero: Permanence and correlation of early postnatal changes in anogenital distance and nipple retention with malformations in androgen-dependent tissues. *Toxicological Sciences: An Official Journal of the Society of Toxicology*, 62(2), 236–249. <https://doi.org/10.1093/toxsci/62.2.236>

Mendonca, B., Bloise, W., Arnhold, I., Batista, M., Toledo, S., Drummond, M., Nicolau, W., & Mattar, E. (1987). Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: Gender role change and absence of gynecomastia at puberty. *Journal of Steroid Biochemistry*, 28(6), 669–675. [https://doi.org/10.1016/0022-4731\(87\)90396-7](https://doi.org/10.1016/0022-4731(87)90396-7)

Mendonca, B., Inacio, M., Arnhold, I., Costa, E., Bloise, W., Martin, R., Denes, F., Silva, F., Andersson, S., Lindqvist, A., & Wilson, J. (2000). Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. *Medicine*, 79(5), 299–309. <https://doi.org/10.1097/00005792-200009000-00003>

Meuffels, J., Luther-Binoir, I., Daffue, W., Deacon, F., & Mitchell, E. P. (2020). Testicular disorder of sexual development with cryptorchidism, penile hypoplasia and hypospadias in a giraffe (*Giraffa camelopardalis giraffa*). *JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION*, 91. <https://doi.org/10.4102/jsava.v91i0.1971>

- Murakami, T. (2008). Anatomical Examination of Hypospadias in Cattle. *Journal of the Japan Veterinary Medical Association*, 61(12), 931–935. <https://doi.org/10.12935/jvma1951.61.931>
- Murashima, A., Kishigami, S., Thomson, A., & Yamada, G. (2015). Androgens and mammalian male reproductive tract development. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*, 1849(2), 163–170. <https://doi.org/10.1016/j.bbagr.2014.05.020>
- Mylchreest, E., Cattley, R., & Foster, P. (1998). Male reproductive tract malformations in rats following gestational and lactational exposure to Di(n-butyl) phthalate: An antiandrogenic mechanism? *Toxicological Sciences: An Official Journal of the Society of Toxicology*, 43(1), 47–60. <https://doi.org/10.1006/toxs.1998.2436>
- Mylchreest, E., Sar, M., Cattley, R., & Foster, P. (1999). Disruption of androgen-regulated male reproductive development by di(n-butyl) phthalate during late gestation in rats is different from flutamide. *Toxicology and Applied Pharmacology*, 156(2), 81–95. <https://doi.org/10.1006/taap.1999.8643>
- Nassar, N., Abeywardana, P., Barker, A., & Bower, C. (2010). Parental occupational exposure to potential endocrine disrupting chemicals and risk of hypospadias in infants. *Occupational and Environmental Medicine*, 67(9), 585–589. <https://doi.org/10.1136/oem.2009.048272>
- Neocleous, V., Sismani, C., Shammass, C., Efstathiou, E., Alexandrou, A., Ioannides, M., Argyrou, M., Patsalis, P., Phylactou, L., & Skordis, N. (2012). Duplication of exons 3-10 of the HSD17B3 gene: A novel type of genetic defect underlying 17 beta-HSD-3 deficiency. *GENE*, 499(2), 250–255. <https://doi.org/10.1016/j.gene.2012.03.031>
- New, M. (1970). Male pseudohermaphroditism due to 17 alpha-hydroxylase deficiency. *The Journal of Clinical Investigation*, 49(10), 1930–1941. <https://doi.org/10.1172/JCI106412>
- Nightingale, J., Chaudhary, K. S., Abel, P. D., Stubbs, A. P., Romanska, H. M., Mitchell, S. E., Stamp, G. W. H., & Lalani, E.-N. (2003). Ligand Activation of the Androgen Receptor Downregulates E-Cadherin-Mediated Cell Adhesion and Promotes Apoptosis of Prostatic Cancer Cells. *Neoplasia*, 5(4), 347–361. [https://doi.org/10.1016/S1476-5586\(03\)80028-3](https://doi.org/10.1016/S1476-5586(03)80028-3)
- Nowacka-Woszek, J., Szczerbal, I., Salamon, S., Kociucka, B., Jackowiak, H., Prozorowska, E., Slaska, B., Rozanska, D., Orzelski, M., Ochota, M., Dzimira, S., Lipiec, M., Nizanski, W., & Switonski, M. (2014). Testicular disorder of sex development in four cats with a male karyotype (38,XY; SRY-positive). *Animal Reproduction Science*, 151(1–2), 42–48. <https://doi.org/10.1016/j.anireprosci.2014.10.001>
- Okuyama, A., Namiki, M., Koide, T., Itatani, H., Nishimoto, N., Mizutani, S., Sonoda, T., Aono, T., & Matsumoto, K. (1981). Pituitary and gonadal function in prepubertal and pubertal boys with hypospadias. *Acta Endocrinologica*, 98(3), 464–469. <https://doi.org/10.1530/acta.0.0980464>
- Ostby, J., Kelce, W. R., Lambright, C., Wolf, C. J., Mann, P., & Gray, L. E. (1999). The fungicide procymidone alters sexual differentiation in the male rat by acting as an androgen-receptor antagonist in vivo and in vitro. *Toxicology and Industrial Health*, 15(1–2), 80–93. <https://doi.org/10.1177/074823379901500108>
- Ostby J, Monosson E, Kelce WR, & Gray, L. J. (1999). Environmental antiandrogens: Low doses of the fungicide vinclozolin alter sexual differentiation of the male rat. *Toxicology and Industrial Health*, 15(1), 48–64. <https://doi.org/10.1177/074823379901500106>
- Pang, S., Levine, L., Stoner, E., Opitz, J., Pollack, M., Dupont, B., & New, M. (1983). Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function. *The Journal of Clinical Endocrinology and Metabolism*, 56(4), 808–818. <https://doi.org/10.1210/jcem-56-4-808>
- Parks, L. G., Ostby, J. S., Lambright, C. R., Abbott, B.D., Klinefelter, G. R., Barlow, N. J., & Gray LE Jr. (2000). The Plasticizer Diethylhexyl Phthalate Induces Malformations by Decreasing Fetal Testosterone Synthesis during Sexual Differentiation in the Male Rat. *Toxicological Sciences*, 58(2), 339–349. <https://doi.org/10.1093/toxsci/58.2.339>
- Perrone, L., Criscuolo, T., Sinisi, A., Graziani, M., Manzo, T., Sicuranza, R., Bellastella, A., & Faggiano, M. (1985). Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect. *Acta Endocrinologica*, 110(4), 532–539. <https://doi.org/10.1530/acta.0.1100532>
- Prahalada, S., Tarantal, A., Harris, G., Ellsworth, K., Clarke, A., Skiles, G., MacKenzie, K., Kruk, L., Ablin, D., Cukierski, M., Peter, C., vanZwieten, M., & Hendrickx, A. (1997). Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (*Macaca mulatta*). *Teratology*, 55(2), 119–131. [https://doi.org/10.1002/\(SICI\)1096-9926\(199702\)55:2%253C119::AID-TERA1%253E3.0.CO;2-Z](https://doi.org/10.1002/(SICI)1096-9926(199702)55:2%253C119::AID-TERA1%253E3.0.CO;2-Z)
- Rabbani, B., Mahdih, N., Ashtiani, M. H., Setoodeh, A., & A Rabbani. (2012). In silico structural, functional and pathogenicity evaluation of a novel mutation: An overview of HSD3B2 gene mutations. *Gene*, 503(2), 215–221. <https://doi.org/10.1016/j.gene.2012.04.080>
- Raboch, J., Pondelickova, J., & Starka, L. (1976). Plasma testosterone values in hypopspadiacs. *Andrologia*, 8(3), 255–258. <https://doi.org/10.1111/j.1439-0272.1976.tb02144.x>
- Radpour R, Rezaee M, Tavasoly A, Solati S, & Saleki A. (2007). Association of long polyglycine tracts (GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile hypospadias in Iranian patients. *Journal of Andrology*, 28(1), 164–169. <https://doi.org/10.2164/jandrol.106.000927>
- Ratan, S., Aggarwal, S., Mishra, T., Saxena, A., Yadav, S., Pandey, R., Sharma, A., & Dhanwal, D. (2012). Children with isolated

- hypospadias have different hormonal profile compared to those with associated anomalies. *Journal of Pediatric Endocrinology & Metabolism : JPEM*, 25(1), 111–119. <https://doi.org/10.1515/jpem.2011.421>
- Rittmaster, R. S., & Wood, A. J. J. (1994). Finasteride. *New England Journal of Medicine*, 330(2), 120–125. <https://doi.org/10.1056/NEJM199401133300208>
- Schaufele, F., Carbonell, X., Guerbado, M., Borngraeber, S., Chapman, M. S., Ma, A. A. K., Miner, J. N., & Diamond, M. I. (2005). The structural basis of androgen receptor activation: Intramolecular and intermolecular amino–carboxy interactions. *Proceedings of the National Academy of Sciences*, 102(28), 9802–9807. <https://doi.org/10.1073/pnas.0408819102>
- Schlomer, B. J., Feretti, M., Rodriguez, E. J., Blaschko, S., Cunha, G., & Baskin, L. (2013). Sexual differentiation in the male and female mouse from days 0 to 21: A detailed and novel morphometric description. *The Journal of Urology*, 190(4 Suppl), 1610–1617. <https://doi.org/10.1016/j.juro.2013.02.3198>
- Sharpe, R. M. (2020). Androgens and the masculinization programming window: Human-rodent differences. *Biochemical Society Transactions*, 48(4), 1725–1735. <https://doi.org/10.1042/BST20200200>
- Sherbet, D., Tiosano, D., Kwist, K., Hochberg, Z., & RJ Auchus. (2003). CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. *The Journal of Biological Chemistry*, 278(49), 48563–48569. <https://doi.org/10.1074/jbc.M307586200>
- Simard, J., Luthy, I., Guay, J., Bélanger, A., & Labrie, F. (1986). Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. *Molecular and Cellular Endocrinology*, 44(3), 261–270. [https://doi.org/10.1016/0303-7207\(86\)90132-2](https://doi.org/10.1016/0303-7207(86)90132-2)
- Sinclair, A., Cao, M., Pask, A., Baskin, L., & Cunha, G. (2017). Flutamide-induced hypospadias in rats: A critical assessment. *Differentiation; Research in Biological Diversity*, 94, 37–57. <https://doi.org/10.1016/j.diff.2016.12.001>
- Smith, K., Brown, P., & Barr, F. (2012). A Survey of Congenital Reproductive Abnormalities in Rams in Abattoirs in South West England. *Reproduction in Domestic Animals*, 47(5), 740–745. <https://doi.org/10.1111/j.1439-0531.2011.01952.x>
- Sonne, C., Dietz, R., Born, E. W., Leifsson, P. S., & Andersen, S. (2008). Is there a link between hypospadias and organochlorine exposure in East Greenland sledge dogs (*Canis familiaris*)? *Ecotoxicology and Environmental Safety*, 69(3), 391–395. <https://doi.org/10.1016/j.ecoenv.2007.09.008>
- Stamper, M. A., Norton, T., Spodnick, G., Marti, J., & Loomis, M. (1999). Hypospadias in a polar bear (*Ursus maritimus*). *Journal of Zoo and Wildlife Medicine: Official Publication of the American Association of Zoo Veterinarians*, 30(1), 141–144.
- Svensson, J., Eneroth, P., Gustafsson, J., Ritzén, M., & Stenberg, A. (1979). Reduction of androstenedione by skin in vitro and serum levels of gonadotrophins and androgens in men with hypospadias. *The Journal of Endocrinology*, 82(3), 395–401. <https://doi.org/10.1677/joe.0.0820395>
- Switonski, M., Dzimira, S., Aleksiewicz, R., Szczerbal, I., Nowacka-Woszek, J., Krzeminska, P., Deska, T., & Nizanski, W. (2018). Hypospadias Is Not Rare in Dogs: Five New Cases, a Retrospective Study, and a Review of the Literature. *Sexual Development: Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation*, 12(5), 244–250. <https://doi.org/10.1159/000490079>
- van den Driesche, S., Kilcoyne, K., Wagner, I., Rebouret, D., Boyle, A., Mitchell, R., McKinnell, C., Macpherson, S., Donat, R., Shukla, C., Jorgensen, A., Meyts, E., Skakkebaek, N., & Sharpe, R. (2017). Experimentally induced testicular dysgenesis syndrome originates in the masculinization programming window. *JCI Insight*, 2(6), e91204. <https://doi.org/10.1172/jci.insight.91204>
- van den Driesche, S., Shoker, S., Inglis, F., Palermo, C., Langsch, A., & Otter, R. (2020). Systematic comparison of the male reproductive tract in fetal and adult Wistar rats exposed to DBP and DINP in utero during the masculinisation programming window. *Toxicology Letters*, 335, 37–50. <https://doi.org/10.1016/j.toxlet.2020.10.006>
- Wang, S., Shi, M., Zhu, D., Mathews, R., & Zheng, Z. (2018). External Genital Development, Urethra Formation, and Hypospadias Induction in Guinea Pig: A Double Zipper Model for Human Urethral Development. *Urology*, 113, 179–186. <https://doi.org/10.1016/j.urology.2017.11.002>
- Wang, S., & Zheng, Z. (2025). Differences in Formation of Prepuce and Urethral Groove During Penile Development Between Guinea Pigs and Mice Are Controlled by Differential Expression of Shh, Fgf10 and Fgfr2. *Cells*, 14(5), 348. <https://doi.org/10.3390/cells14050348>
- Welsh, M., Saunders, P., Fiskin, M., Scott, H., Hutchison, G., Smith, L., & Sharpe, R. (2008). Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. *The Journal of Clinical Investigation*, 118(4), 1479–1490. <https://doi.org/10.1172/JCI34241>
- Willingham, E., Agras, K., Souza, A. J. de, Konijeti, R., Yucel, S., Rickie, W., Cunha, G., & Baskin, L. (2006). Steroid receptors and mammalian penile development: An unexpected role for progesterone receptor? *The Journal of Urology*, 176(2), 728–733. <https://doi.org/10.1016/j.juro.2006.03.078>
- Wolf, C., LeBlanc, G., Ostby, J., & Gray, L. J. (2000). Characterization of the period of sensitivity of fetal male sexual development to vinclozolin. *Toxicological Sciences: An Official Journal of the Society of Toxicology*, 55(1), 152–161. <https://doi.org/10.1093/toxsci/55.1.152>

Yadav, C., Bajpai, M., Kumar, V., Datta, S., Gupta, P., Ahmed, R., & Banerjee, B. (2011). Polymorphisms in the P450 c17 (17-hydroxylase/17, 20-Lyase) gene: Association with estradiol and testosterone concentration in hypospadias. *Urology*, 78(4), 902–907. <https://doi.org/10.1016/j.urology.2011.04.021>

Yu, X., Nassar, N., Mastroiacovo, P., Canfield, M., Groisman, B., Bermejo-Sánchez, E., Ritvanen, A., Kiuru-Kuhlefelt, S., Benavides, A., Sipek, A., Pierini, A., Bianchi, F., Källén, K., Gatt, M., Morgan, M., Tucker, D., Canessa, M. A., Gajardo, R., Mutchinick, O. M., ... Agopian, A. J. (2019). Hypospadias Prevalence and Trends in International Birth Defect Surveillance Systems, 1980-2010. *European Urology*, 76(4), 482–490. <https://doi.org/10.1016/j.eururo.2019.06.027>

Yucel, S., Liu, W., Cordero, D., Donjacour, A., Cunha, G., & Baskin, L. (2004). Anatomical studies of the fibroblast growth factor-10 mutant, Sonic Hedge Hog mutant and androgen receptor mutant mouse genital tubercle. *Advances in Experimental Medicine and Biology*, 545, 123–148. https://doi.org/10.1007/978-1-4419-8995-6_8

Zheng, Z., Armfield, B., & Cohn, M. (2015). Timing of androgen receptor disruption and estrogen exposure underlies a spectrum of congenital penile anomalies. *Proceedings of the National Academy of Sciences of the United States of America*, 112(52), E7194–203. <https://doi.org/10.1073/pnas.1515981112>